

Subject Index

A

A. fumigatus

- fungi 918
- PTX3 169–170

A. fumigatus conidia 171

a proliferation-inducing ligand *see* APRIL

aberrant DC maturation, filoviruses
833–834

abundant cell population, human cancer
1085

AC *see* anterior chamber

ACAID 107–109

- F4/80 protein 109
- therapeutic potential 110
- *see also* anterior chamber associated
immune deviation

ACAMP, apoptotic cells 593

Acanthocheilonema viteae 412, 712

accumulation of mature DC, asthma
1066–1068

acid-fastness, tuberculosis 748

acquired immune system, presentation 151

acquired immunity 182–183

- malaria 653–654

acquisition of antigens, crosspresentation
428–436

activated DC

- defective downregulation 942
- tolerance induction 574

activated NKT cells

- immunomodulatory functions 326
- metastasis 325

activating signals

- DC-CTL interaction 466–468
- T cell priming 348

activation

- CTL 462–463
- DC-mediated 483–484
- NK cells 482–484

activation-induced cell death, tolerance
induction 570

activator, DC function 694

active immunization, EBV 905

adaptive immune response 253, 1017

- cytokines 355

- fungi 916

adaptive immunity

- autoimmune diseases 935
- DC-NK cross-talk 487–489
- graft rejection 972–973
- *Salmonella* 734–737

adaptive regulators, pharmacologically
modified DC 619

adaptive regulatory T cells 406

- asthma 1065

adaptive Treg, transplantation tolerance
992

ADCC, NK cells 483

ADCI, malaria 655

adeno-associated virus vectors, adenovirus
1149

adenoviral antigen delivery 1151, 1153

adenoviral gene transfer, therapeutic
vaccination 1145–1153

adenovirus

- adeno-associated virus vectors 1149
- adenoviral Ag delivery 1153
- capsid structure 1147
- E3 gene region 1149
- endocytosis 1146
- first generation vectors 1146
- gene transfer into DC *in vitro* 1149–1151
- gene transfer vectors targeting 1148
- genome structure 1147
- *Herpes simplex* virus vectors 1149
- HIV/SIV vaccination in monkeys 1153
- infection cycle 1148
- *Influenza* virus vectors 1149
- lentivirus 1149
- multiple Ag loading
- retrovirus 1149
- transduced cells 1146

- transductional targeting 1148
- tropism-modification 1150
- *Vaccinia* virus-based vectors 1149
- virions 1146
- virus internalization 1146
- adhesion, malaria 657
- adhesion molecules, exosomes 501
- adhesion receptors, CLR 131–133
- adjuvant immunotherapy, renal cell carcinoma 1122–1123
- adjuvant-like effect, NKT cells 327
- adjuvants, DC activation 796
- adoptive T cell therapy, EBV 904
- adsorptive endocytosis 5
- adult epidermis, Langerhans cells 77–78
- adverse effects, renal cell carcinoma 1123–1124
- AE *see* anchor enzyme
- Aedes aegypti*, DEN 835
- Aedes albopictus*, DEN 835
- AEDS, fungi 925
- afferent lymph 280
- afferent lymph dendritic cells, origin 283
- affinity maturation, protein swapping 508
- Ag *see* antigens
- AIDS 773
 - *see also* HIV
- AIRE, tolerance induction 569
- airway obstruction, asthma 1059
- aldrithiol-2, HIV infection 792
- allergen, asthma 1062–1065
- allergen challenge 1072
- allergies 7, 1047–1080
 - semi-mature DC 529
 - T cell tolerance 520
- alloantigen presentation 967–971, 988
 - CRT 988
 - graft rejection 970–971
 - graft-versus-host disease 973–977
 - transplantation tolerance 985–986
- alloantigen-pulsed Rapa-DC 1033
- alloantigen recognition, graft rejection 967–970
- allogeneic hematopoietic stem cell transplantation *see* HSCT
- allogeneic T cells, human 391
- allograft rejection
 - graft rejection 967
 - immune regulation 1017
 - transplantation tolerance 985–989
- allograft survival, transplant tolerance 1026
- alloreactive T cells
 - central deletion 997–1000
 - graft-versus-host disease 973–974
 - HCMV 818
 - peripheral regulation 1000–1001
- allorecognition pathways
 - graft rejection 968
 - immune regulation 1020
- alteration of DC function, LV 839
- Alzheimer's disease, HSV 878
- amastigote form, Leishmaniasis 669
- amplification 33
- anchor enzyme, pharmacologically modified DC 624
- anergy
 - immature DC 525
 - measles virus 855
 - T cell tolerance 519, 1023
- animal models
 - malaria 653–656
 - measles virus 859
- Anopheline* mosquito, malaria 651
- anterior chamber
 - DCAPC 105–107
 - eye 101
- anterior chamber associated immune deviation 106
 - *see also* ACAID
- anti-envelope antibodies, HIV infection 789
- anti-inflammatory capacities, ES-62 412
- anti-inflammatory lipid mediators 305
- anti-inflammatory state, fungi 924
- anti-TNF therapy, autoimmune diseases 949
- antiangiogenic activity, TSP-1 147
- antibodies
 - anti-Ia 74
 - monoclonal 363
- antibodies-dependent cellular cytotoxicity *see* ADCC
- antibodies-dependent cellular inhibition assay *see* ADCI
- antibodies production, intestinal epithelium 760
- antibodies synthesis, model 287
- antifungal resistance, Th1-dependent 926
- antigen capture
 - C-type lectin receptors 573
 - DC 3
- antigen delivery 1129–1172
 - adenovirus 1153
 - therapeutic vaccination 1145–1153
 - transplantation tolerance 995
- antigen doses, Th-cell responses 387
- antigen entry
 - DC vaccination 1133–1134
 - intestinal bacteria 760

- mucosal surface 760
- antigen internalization 151
- antigen loading 1129
 - cancer vaccines 1096, 1103–1104
 - DC vaccination 1136–1137
- antigen localization, tolerance induction 1022
- antigen positive DC, EBOV 832
- antigen preparation, Leishmaniasis 685
- antigen presentation 313–342, 428
 - CRT 988–989
 - C-type lectins 129
 - DC mediated 327
 - DC vaccination 1130
 - HSV-1 884
 - LV 839
 - malaria 654
 - modulating 728–729
 - tolerance induction 572–573
 - *Toxoplasma gondii* 702–703
 - tuberculosis 749–752, 755
 - *see also* APC
- antigen processing 313–342
 - autoimmune diseases 943
- antigen receptors 129–140
 - DC 130
 - homeostatic control 130–131
- antigen source, exosomes 502
- antigen specific immune responses 53
- antigen specific proliferation, fungi 926
- antigen specific T cells
 - C-type lectin receptors 573
 - human cancer 1082
- antigen targeting, T cell priming 347
- antigen transfer
 - exosomes 503
 - living cells 434
- antigen translocation, DC-CTL interaction 464
- antigen transport, lymph dendritic cells 286
- antigen uptake
 - dendritic cells 5
 - intestinal epithelium 760–762
- antigenic cargo, DC vaccination 1134–1135
- antigenic peptide selection, Leishmaniasis 686
- antigenic variation, malaria 652
- antigens
 - asthma 1062–1065
 - autoimmune diseases 935
 - crosspresentation 428–436
 - differentially expressed 225
 - glycolipid 314
 - physical form 440
 - renal cell carcinoma 1122
 - scavenger receptors 152–153
 - tolerance induction 569
 - antigenspecific tolerance 1004
 - transplantation tolerance 985
 - antimicrobial peptides, intestinal epithelium 759
 - antitumor immune responses 240
 - antitumor immunity 323
 - antitumor responses 1081
 - antiviral actions, HIV infection 795
 - antiviral immune responses
 - cytokines production 357
 - HSV-1 880
 - human pDCs 429
 - APC 55, 102, 124, 279, 427
 - CHS 1048
 - dendritic cells 343
 - eye 101–118
 - graft rejection 970
 - humans 234
 - immune regulation 1017
 - NKT cells 322
 - protein swapping 508
 - PTX3-deficient mice 170
 - *see also* antigen presentation
 - apoptosis 39
 - graft rejection 971
 - LV 839
 - MCMV infection 821
 - apoptotic blebs, tuberculosis 754
 - apoptotic-cell-associated molecular patterns
 - *see* ACAMP
 - apoptotic cells 430
 - ACAMP 593
 - autoimmune diseases 938
 - autoimmune response 591
 - backup mechanisms 600
 - CD36 596
 - cell detection 595
 - clearance 155, 594, 600
 - complement factors 596–598
 - CRP 598
 - cytokine gene mRNA transcription 601
 - DC phagocytose 592
 - early 600–602
 - entrapment by splenic DC *in vivo* 605
 - extracellular Ag 592
 - globule protein 598–599
 - β 2-GPI 595
 - HMGB1 608
 - IgM antibodies 597
 - inflammation 592
 - integrin 596, 607

- interaction 591–618
- interaction with DC 591–618
- internalization 604
- lactadherin 598–599
- ligand–receptor pairs 593
- lysophosphatidylcholine 609
- macrophage marker 600
- macrophages 601
- mediating 150
- Mer 600
- MFG-E8 598–599
- MHC class-II molecules 592
- microscopic cell detection 595
- migratory DC 603
- milk-fat globule protein 598–599
- mimicry 607–608
- molecular mechanisms 602–605
- oxidative stress 595
- pathogens 607–608
- peripheral tolerance 605–607
- phagocytes 594
- phagocytic synapse 593
- phagocytose 592
- phagocytosis 155
- PRR 593
- PTX3 598
- receptors involved in recognition 431
- recognition signals 599–600
- redundant receptors 600
- *Salmonella typhimurium* 609
- SAP 598
- self-Ag transport 604
- self-proteins 591
- sugar composition 600
- systemic lupus erythematosus 609
- T cell response 609
- therapeutic use 605–607
- thymocytes 603
- tolerance induction 1004
- tolerogenic DC 523
- *Trypanosoma cruzi* 607
- TSP-1 596
- uptake 152, 155, 286
- uptake by DC 601
- apoptotic material 530
- APRIL 363
- AqH, eye 103, 106
- aqueous humor *see* AqH
- arc of tolerance, eye 108
- arteriosclerosis, tumor necrosis factor-alpha 31
- ASGPR, DC-SIGNR 844
- asialoglycoprotein receptor *see* ASGPR
- aspergillosis, protection 14
- Aspergillus fumigatus*
 - bound by PTX3 167
 - fungi 918
 - receptor exploitation 922
- asthma 1047–1080
 - accumulation of mature DC 1066–1068
 - adaptive regulatory T cells 1065
 - allergen 1062–1065
 - antigens 1062–1065
 - B7 superfamily blocking 1069
 - Birbeck granules 1061
 - *Bordetella pertussis* 1065
 - bronchial smooth muscle cell hypertrophy 1059
 - CD4⁺ T 1066
 - chronic inflammatory disorder 1059
 - DC 1061–1068
 - DC driven Th2 responses 1069–1071
 - DC signaling 1062
 - DC subsets 1061
 - dendrite projections 1061
 - effector Th2 lymphocytes 1060
 - effector Th2 responses 1068–1069
 - epithelial cells-DC interaction 1070
 - functional role for DC 1068–1069
 - GM-CSF 1060
 - IDO 1066
 - immune responses 236, 1062–1065
 - *Listeria* infection 1069–1071
 - OVA 1065
 - OX40L blocking 1069
 - pDC 1066
 - primary immune responses 1062–1065
 - protective immunity to inhaled antigens 1063
 - secondary immune challenge 1066
 - sensitization 1062–1065
 - staining of T cells 1067
 - Th2 driven disorder 1059–1062
 - Th2 response stimulation 1068–1071
 - TNF-R family blocking 1069
- asthmatic inflammation 1066–1068
- AT-2 viruses, HIV infection 792
- atherosclerosis 269
- attachment factor, DC-SIGN 841, 844
- autocrine factor, IL-4 410
- autoimmune diseases 935–966
 - adaptive immunity 935
 - Ag 935, 943
 - anti-TNF therapy 949
 - apoptotic cells 938
 - autoimmunity 940
 - autoreactive T cells 949
 - B cells clonal selection 937

- bystander DC 940
 - central tolerance 936–939
 - cytokine microenvironment 943, 951
 - cytokine-induced DC activation 949–950
 - cytokines 950–951
 - DC 936, 939–951
 - DC generation 950–951
 - defective abnormalities in DC 947
 - EAE 938
 - foreign antigen specific T cells 937
 - IDDM 938
 - IFN- α driven disease 941
 - immature/steady state DCs 938
 - immunity 935, 943, 950
 - inflammatory sites 945
 - microbial infections 940, 950
 - monocytes 941
 - negative selection 937
 - peripheral tolerance 938, 946–947
 - priming 939–945
 - self antigen presentation 938, 946
 - self antigen specific T cells 937
 - SLE 938
 - T cells 937, 944, 949
 - Th1/Th2 imbalance 944
 - tissue infiltration by DC 945
 - TNF 949
 - tolerance 936–939
 - tolerogenic DC subsets 944
 - type I interferons 949
 - vicious circle 945
 - autoimmune myocarditis 938
 - autoimmune regulator protein *see* AIRE
 - autoimmune response, apoptotic cells 591
 - autoimmunity 935–966
 - autoimmune diseases 940
 - B-cell regulation 239
 - DC migration 303
 - DC subsets 942–945
 - induction 574
 - autoreactive NKT cells 323
 - autoreactive T cells, autoimmune diseases 949
- B**
- B cells 208, 286
 - activating factor 363
 - autoimmune diseases 937
 - CD1d-presentation 317
 - EBV 900
 - EBV-transformed 898
 - follicles 286
 - function regulation 239
 - key transcription factor 60
 - *Schistosoma* 716
 - stimulator 360
 - transplant tolerance 1034
 - B-lymphocyte-derived exosomes 501
 - B lymphocytes, exosomes 502
 - B. pertussis* 416
 - B7 superfamily blocking, asthma 1069
 - Bacille Calmette-Guerin *see* BCG
 - Bacillus subtilis* 763
 - background, genetic 388
 - backup mechanisms, apoptotic cells 600
 - bacteria 723–772
 - DC-NK cross-talk 491
 - intestinal 759–772
 - lipopolysaccharides 119
 - pathogen elimination 723
 - phagocytosis 723
 - recognition 148
 - response-skewing cytokines 723
 - bacterial uptake
 - intestinal bacteria 761
 - *Salmonella* 724–727
 - Bacteroides thetaiotamicron* 763
 - balance, immunity and tolerance 608
 - baseline extravasation of monocytes 268
 - BCG (Bacille Calmette-Guerin)
 - IL-27R-deficient mice 411
 - SR-A deficient mice 143
 - tuberculosis 745, 749
 - BDCA2, cancer vaccines 1097
 - BDCA4 cells, activation 232
 - Bet v 1 allergen, immune balance 520
 - bidirectional interactions 1038
 - bidirectional signaling, fungi 925
 - bidirectional transfer, proteins 505
 - binding, exosomes 501–502
 - binding properties, mammalian scavenger receptors 142–150
 - binding proteins
 - DNA 54
 - zinc finger 54
 - biological mechanism, sage library comparisons 634–636
 - biologically relevant peptides, therapeutic vaccination 1144
 - Birbeck granules 42, 84
 - asthma 1061
 - birth defects, HCMV 813
 - blocking mucosal infection, HIV 793–794
 - blood
 - human DC 225
 - T cell responses 1106
 - blood-circulating, myeloid DC 169–170
 - blood-circulating myeloid, PTX3 169–170

- blood monocytes 254–256
 - differentiation 262
 - elimination 266
 - mononuclear phagocyte system 254–256
 - recruitment 262
- bone-marrow derived DC, tolerance induction 570
- bone marrow-derived plasmacytoid DC, Th-cell responses 387
- bone marrow-derived resident cells 258–259
- bone marrow progenitors
 - dendritic cells 13
 - HCMV 815
 - interferon-producing cells 13
- bone marrow transplantation, graft-versus-host disease 973
- Bordetella pertussis* 408, 416
 - asthma 1065
 - expression profile of pathogens 181
- bovine spongiform encephalopathy 287
- breast cancer 240
- bronchial smooth muscle cell hypertrophy, asthma 1059
- Brucella abortus* 393
- Bsm F1 625
- bunyavirus family, HTV 840
- Burkholderia cepacia*, PTX3 167
- bystander APC 729–730
- bystander DC
 - autoimmune diseases 940
 - DEN 837
- C**
- C. neoformans*, fungi 926
- C reactive protein (CRP) 598
 - pentraxin superfamily 165
- C-type lectin receptors 84
 - DC vaccination 1133
 - tolerance induction 571–573
 - tumor associated cea recognition 137
- C-type lectins 407
 - antigen capture 573
 - antigen presentation 129
 - antigen-specific T cells 573
 - cellular communications 133
 - CLR
 - dendritic cells 129–140
 - ligation 416
 - *Schistosoma* 713
 - tuberculosis 747
 - type II transmembrane proteins 408
- Ca²⁺ influx, T cell tolerance 519
- canarypox vectors, HIV vaccines 795
- cancer 240, 1081–1128
 - DC subsets 1095–1116
 - DC-NK cross-talk 491–493
 - humoral immunity 1095
 - immunotherapy 88, 1095
 - therapeutic vaccination 1143
 - tumor necrosis factor-alpha 31
 - vaccination 1095–1116
 - cancer immunosurveillance, renal cell carcinoma 1117–1118
 - cancer recognition, CLR 137
 - cancer vaccines 1095–1097
 - antigen loading 1096, 1103–1104
 - BDCA2 1097
 - clinical efficacy 1106–1107
 - control antigens
 - DC 1097–1104
 - DC-SIGN 1097
 - gold standard method 1101
 - heteroclitic peptides 1104
 - IL15-DC 1101
 - IL4-DC 1100
 - immune effectors 1106
 - immune response induction 1099–1100
 - immune tolerance 1100
 - immunization 1102
 - immunological efficacy 1106–1107
 - maturation stimuli 1101
 - peptide-pulsed DCs 1102
 - pro-inflammatory cytokines 1101
 - regulatory mechanisms 1104–1106
 - suppressor mechanisms 1104–1106
 - T cell immunity 1097
 - T cell polarization 1100
 - TAA 1103
 - therapeutic T cell immunity 1097
 - tissue antigen presentation 1100
 - vaccination frequency 1103
 - vaccine efficacy
 - Candida albicans* 415
 - fungi 915, 918
 - mannose-containing carbohydrates 135
 - PTX3 167
 - receptor exploitation 922
 - Th-cell responses 390
 - Candida hyphae* 348
 - Candida* infection 524
 - candidate genes, tolerance associated 630, 636–638
 - candidate precursors, LC induction 41
 - candidiasis, fungi 924
 - capsid structure, adenovirus 1147
 - carbohydrate components, *Schistosoma* 713
 - carbohydrate recognition domains, tolerance induction 571

- carbohydrate-recognizing CLRs, intracellular routing 129
- carcinoma embryonic antigen 137
- carrageenans, HIV infection 788
- carrier proteins, CHS 1051–1052
- caspase-1, IL-18 synthesis 359
- cathelicidins, chemotactic factors 302
- cathepsin S 316
- CBD *see* chronic beryllium disease
- CCR2⁺ CX3CR1^{high} monocytes 266
- CCR2⁺ CX3CR1^{low} monocytes 266
- CD lysis, NK cells 485–486
- CD1d cells 313–342
- CD1d-expressing APC 316–321
- CD1d-expressing cells, cross-talk 322
- CD1d molecule 313–315
- CD1d presentation 313–318
- CD1d-restricted NKT Cells 318–319, 328
- CD4⁺CD25⁺, DC-NK cross-talk 489–490
- CD4⁺ T, asthma 1066
- CD4⁺ T lymphocytes defect, HCMV 813
- CD8 T cells, malaria 654
- CD8-positive T cells, CHS 1051
- CD8 α , generation 16
- CD8⁺, cytotoxic T lymphocyte response 455
- CD8⁺ T cells 427
- CD8a expression, transplantation tolerance 990–991
- CD11c expression 204
- CD11c positive cell fraction 18
- CD11c⁺CD8 α ⁻ DC, Th-cell responses 389, 392
- CD11c⁺CD8 α ⁺ DC, Th-cell responses 388, 392
- CD14⁺ cells, renal cell carcinoma 1119
- CD14⁺ intermediates 33
- CD28, signaling process 343
- CD34⁺ cells 33
- CD34⁺ hematopoietic progenitor cells 27
- LC differentiation 41
- CD34⁺ progenitors, cellular heterogeneity 43
- CD36 147–148
- apoptotic cells 596
- expression 153
- malaria 657
- CD38, nonchemotactic signals 305
- CD4-positive T Cells, CHS 1048–1051
- CD40 ligation, measles virus 863
- CD45RA expression 204
- CD46, measles virus 857
- CD68, mouse macroscialin 149–150
- CD83, HSV-1 885–888
- CD94/NKG2A inhibitory receptor, NK cells 485
- CD1asuper + myeloid DC subsets, cytokines 33
- CD209-dependence, HIV infection 783
- cDC *see* conventional DC
- CEA *see* carcinoma embryonic antigen
- C/EBP α 57
- cell activation, modulation 155
- cell apoptosis, graft rejection 971
- cell biology
- DC 1–648
- scavenger receptors 150–156
- cell-cell contact protein transfer 504–506
- cell cluster 631
- protein swapping 508
- cell contact, direct 393
- cell death
- exosomes 503
- interaction with DC 591
- *Salmonella* induced 730
- tolerance induction 570
- cell derived factors, intestinal epithelium 766
- cell detection, apoptotic cells 595
- cell development 18–20
- transcription factor network 53–71
- unexpected redundancy 16–17
- cell differentiation, proposed models 15–16
- cell entry, HSV-1 875, 879–880
- cell factors, Th2-cell development 395
- cell fate
- CEPB α 57
- T cell differentiation 346
- cell fraction, CD11c positive MHC class ii negative 18
- cell interaction 387
- cell killing, cytotoxic T lymphocyte response 455
- cell lysates, stimulatory properties 432
- cell nibbling, crosspresentation of ag 153–155
- cell precursors 17
- cell-promoting DC, Th1 414–415
- cell-promoting factors
- Th1 408–410
- Th2 410
- cell replacement therapy *see* CRT
- cell surface molecule CD83, HSV-1 885–888
- cell surface receptors, immune regulation 1018
- cell type
- mysterious 219–221
- self-tolerance 989
- cell wall, mycobacteria 748

- cells
 - antigen presenting 170
 - antigen-presenting 101–118
 - apoptotic 152
 - Langerhans 73–100
 - profiling 180–182
- cellular adhesion 132
- cellular communications, C-type lectins 133
- cellular entry, HTV 840
- cellular heterogeneity, DC 43
- cellular immunity, malaria 654
- cellular innate immunity 165–174
- cellular markers, transplant tolerance 1034–1035
- cellular PRR 165
- cellular surface molecules, measles virus 858
- central deletion, alloreactive T cells 997–1000
- central tolerance 570
 - autoimmune diseases 936–939
- cercarial-derived prostaglandins, *Schistosoma* 717
- CFU *see* colony-forming unit
- chaperones
 - cleavage 316
 - heat-shock proteins 432
- chemerin
 - chemotactic factors 302
 - graft rejection 972
- chemoattractants, HIV infection 794
- chemokine receptors 269, 296
 - coupling 303
 - HIV infection 778
 - Leishmaniasis 677–678
 - pDCs-IPCs 227
- chemokines 5
 - epithelial infection 762
 - human cancer 1085
 - Leishmaniasis 677–678
 - migratory cells 296–298
 - T cell activation 343
- chemotactic factors
 - cathelicidins 302
 - chemerin 302
 - defensins 302
 - dendritic cells 301–303
 - inflammation site 301
 - migratory cells 295
 - nonchemokine 301
- chinese medicine, myriocin 304
- chromatin-binding protein, HMGB1 608
- chronic beryllium disease, CHS 1053
- chronic infection 7
 - chronic inflammatory disorder 4
 - asthma 1059
- chronic myeloid leukemia *see* CML
- chronic rejection treatment, DC therapy 1033–1034
- CHS (contact hypersensitivity) 1047–1058
 - APC metabolism 1048
 - carrier proteins 1051–1052
 - CD8-positive T cells 1051
 - CD4-positive T Cells 1048–1051
 - chronic beryllium disease 1053
 - contact allergens 1047
 - covalently modified peptides 1047
 - cryptic peptide epitopes 1050–1051
 - gold-specific T cells 1050
 - hapten 1047
 - hapten-like Ni epitopes 1049–1050
 - hapten-peptide determinants 1048
 - heat shock proteins 1052–1053
 - HLA-restrictions 1048–1049
 - HMD 1053
 - HSA 1051
 - intermediate contact sites 1053
 - LC 1047
 - metal alloys 1048
 - metal-specific T cells 1050
 - MHC-associated peptides 1049
 - Ni²⁺ ions 1049
 - nickel contact dermatitis 1048
 - nickel presentation 1049–1051
 - nickel transport 1052
 - nickel-binding proteins 1051–1053
 - non-HLA restricted nickel presentation 1051
 - peptides 1047
 - sensitization phase 1047
 - skin-sensitizers 1047
 - T cell clones 1049
- circulating DC subsets, HIV virus effects 791
- circulating dendritic cells 261–262
 - precursors 219–278
- circulating monocytes, half-life 267
- CL-P1 *see* Collectin placenta 1
- class A scavenger receptors 143–147
- class B SR family, CD36 147
- classical endocytic pathway, entry 436–438
- clinical efficacy, cancer vaccines 1106–1107
- clinical grade DC, renal cell carcinoma 1119–1120
- clinical relevance, tolerance associated 638
- clinical trials, renal cell carcinoma 1120–1122
- clinical use, DC therapy 1035

- clinical vaccination, DC vaccination
1136–1137
- clonal anergy, tolerance induction 569
- clonal deletion, tolerance induction 569
- cloning, ES cells 1007
- Clostridium difficile* 438
- CLP *see* common lymphoid progenitors
- CLR
- adhesion receptors 131–133
 - cancer recognition 137
 - cellular function understanding 138
 - C-type lectins
 - homeostatic control 130–131
 - internalization 133
 - pathogen receptors 133
 - physiological function 131
 - signaling receptors 136
 - tolerance induction 571
- CML, DC-NK cross-talk 491
- CMP *see* common myeloid progenitors
- CMV *see also* HCMV, MCMV, 813–828
- DC function damping 822
 - immune response damping 822
 - infection 813–828
 - pathology 814
 - T cell-mediated immune responses 822
- co-circulating genotypes,
measles virus 856
- co-infection with HIV, tuberculosis 747
- co-infections, HIV 792
- co-receptor, HIV infection 776
- co-signaling
- DC-CTL interaction 465
 - LC differentiation 39
- co-stimulation 313–384
- fungi 921
 - graft rejection 968
 - *Salmonella* 735
 - signal 2 343
 - Th-cell responses 388
- cobalt-induced hard metal lung disease
- coiling phagocytosis, fungi 918
- collagen-induced arthritis, semi-mature DC
529
- Collectin placenta 1 (CL-P1) 146
- collectins 597
- fungi 923
- colony-forming unit DC 36
- combinations, T cell tolerance
- common lymphoid progenitors 14, 16, 259
- common myeloid progenitors 14, 259
- common variable immunodeficiency,
defective abnormalities in DC 947
- communication, intercellular 499–516
- communication modes, DC-CTL interaction
456
- comparative SAGE resource 628
- complement, malaria 658
- complement cascade, activation 597
- complement factors, apoptotic cells
596–598
- complement receptors
- tolerance induction 578
 - type 3 408
- complexes, MyD88-IRAK4-TRAF6-IRF-7
231
- concepts, Th-cell responses 388–392
- constitutive migration, dendritic cells
281–282
- contact allergens, CHS 1047
- contact-dependent protein transfer 504–506
- contact hypersensitivity *see* CHS
- control antigens, cancer vaccines
- conventional DC 203–204
- conventional myeloid DC 237–238
- conventional T cells, DC-NK cross-talk
489–490
- cornea, DCAPC 105
- cortico-medullary junction 208
- covalently modified peptides, CHS 1047
- CpG-containing bacterial DNA 413
- CpG ISS-ODN, DC activation 796
- CR *see* complement receptors
- cross-talk
- APC 322
 - CD1d-expressing cells 322
 - DC 481–516
 - DC-CTL interaction 487–490
 - intestinal bacteria 762–763
 - intestinal epithelium 764–767
 - killer cells 481–498
 - NKT cells 322
 - SR 156
 - Toll-like receptors 156
- cross-tolerance 429
- crosspresentation 124, 427–480, 1129–1142
- antigens 152–153, 428–436
 - cell nibbling 153–155
 - cytoskeleton rearrangement 438
 - DC vaccination 1130–1134, 1137
 - EBV 903
 - HSV-1 881
 - influenza virus 440
 - mechanisms 437
 - MyD88 435
 - pathway 5
 - peptide-chaperone complexes 153–155
 - phagocytosis 438

- pharmacologically modified DC 622
- physiological relevance 442
- protein swapping 509
- receptors 430
- Sec61 439
- sources 430
- TLR 435
- tumor antigens 488
- crosspriming 236, 427
 - ligation of TLR3 436
 - TAP-dependent 440
 - tuberculosis 753–754
- crossprocessing 427–454
- CRP *see* C reactive protein
- CRT
 - alloantigen presentation pathway 988
 - antigen presentation pathway 988–989
 - immune intervention 1005–1007
 - Parkinson's disease 984
 - transplantation tolerance 984
- cryptic peptide epitopes, CHS 1050–1051
- Cryptococcus neoformans*, fungi 918–919
- CTL 455
 - activation 462–463
 - CD8⁺ 455
 - cell killing 455
 - dendritic cells 455–480
 - differentiation 462–463
 - dynamics 455
 - HIV 455
 - interaction 455–480
 - LCMV 455
 - NKT cells 322
 - overshoot 465–466
 - precursors 461
 - priming 427–480
 - responses 427
 - therapeutic vaccination 1143
 - T lymphocytes 455–480
 - TCR 455
- cyclic ADP ribose, synthesis 305
- cynomologous macaques, EBOV 832
- cytokeratin, Langerhans cells 82
- cytokine environments, DC differences 396
- cytokine expression 355
- cytokine family
 - GM-CSF 29
 - transforming growth factor beta-1 32
- cytokine gene mRNA transcription, apoptotic cells 601
- cytokine-induced DC activation, autoimmune diseases 949–950
- cytokine-mediated suppression, T cell tolerance 521
- cytokine microenvironment, autoimmune diseases 943, 951
- cytokine production 837
- cytokine receptor/ligand pair, Flt3 18
- cytokine regulation, DC development 28
- cytokine secretion 322
- cytokine signals
 - DC hematopoiesis regulation 33–43
 - overview 38
 - redundancy 41
- cytokine stimuli 27
- cytokines 3, 5, 33, 224, 405
 - adaptive immune response 355
 - autoimmune diseases 950–951
 - combinations 36–38
 - co-stimulatory 343
 - DC development 28
 - DC differences 396
 - dendritic cells 355–384
 - immune effector cells 321
 - important 28–32
 - *in vitro* cultures 27
 - infection response 355
 - LC differentiation 41
 - monocyte-derived DC 42
 - myeloid DC progenitor cells 35
 - myeloid DC subsets 33
 - pleiotropic 360
 - pro-inflammatory 360, 362
 - receptor/ligand pair 18
 - secretion 323
 - T cell tolerance 1023
 - Th-cell responses 386
- cytokines production
 - antiviral immune responses 357
 - dendritic cells 355–384
 - IFN- α/β 356
 - IL-1 superfamily 359
 - IL-12 357–358
 - IL-18 359
 - IL-23 357–358
 - IL-27 357–358
 - *Mycobacterium tuberculosis* 357
 - selective responsiveness 363
 - subpopulations 355
 - Th1 responses 359
 - Th2 responses 359
- cytokines secretion, filoviruses 833
- cytolytic activity, NK cells 179
- cytolytic effector mechanisms, NKT cells 322
- cytomegalovirus *see* CMV
- cytoskeleton rearrangement
 - crosspresentation 438

- *Salmonella* 725
- cytosol, DC vaccination 1134
- cytotoxic T lymphocytes *see* CTL
- cytotoxicity
 - NK cells 484
 - NKT cells 322
- D**
- DALIS, DC vaccination 1135
- DALY, Leishmaniasis 669
- danger signals
 - HSP 156
 - human cancer 1082
- danger theory model, immune regulation 1019
- data handling, sage software 627
- DC 286, 723
 - antigen capture 3
 - antigen presentation 327
 - antigen receptors 130
 - antigen uptake 5
 - APC 343
 - autoimmune diseases 936
 - bone marrow progenitors 13
 - cancer vaccines 1100–1104
 - cell biology 1–648
 - cellular heterogeneity 43
 - chemotactic factors 301–303
 - circulating 219–278
 - constitutive migration 281–282
 - cross-talk 481–516
 - CTL interaction 455–480
 - C-type lectins 129–140
 - cytokines 355–384
 - cytokines production 355–384
 - cytotoxic T lymphocyte interaction 455–480
 - differentiation 343–354
 - disease 7, 649–1092
 - disease pathogenesis 6–7
 - efferent lymph 4
 - enrichment 203
 - entry 282
 - eye 101–118
 - functional modification 790–793
 - functional phenotype 620
 - functional plasticity 229
 - gene profiling 175–198
 - genetic manipulation 637
 - glycan modifications 134–136
 - hematopoietic lineage 3
 - heterogeneity 285
 - HIV infection 774–776
 - HIV transfer 841
 - human malaria 658–659
 - immune systems 175
 - immunity 182–183
 - immunology 6
 - immunosurveillance agents 183
 - immunotherapeutic use against EBV 904–905
 - immunotherapy 7–8
 - *in vitro*-generated 356
 - *in vivo* differentiation 256
 - infectious diseases 6
 - innate immunity 165–174
 - *Leishmania mexicana* 190–192
 - life history 3
 - lineage 4
 - lymph 282–286
 - lymphocyte responses 4–6
 - lymphoid tissue 203
 - measles virus 862–863
 - measles virus pathogenesis 859–865
 - membrane co-stimulators 5
 - microbial instruction 405–426
 - monocyte subsets 253–278
 - monocyte-derived 42
 - myeloid 165–174
 - mysteries 3–12
 - pathogen interaction 182–183
 - pathogen recognition 134–136
 - pattern recognition receptors 406
 - pharmacologically modified 619–648
 - plasticity 385–404
 - professional migratory cells 295–296
 - progenitors 13
 - rodent malaria 659–660
 - scavenger receptors 141–164
 - secondary lymphoid organs 199–218
 - self-antigens 523
 - semi-mature 284–285
 - sensors of infection 183–185
 - sentinels 73–198
 - spontaneous maturation 355
 - steady state migration 279–294
 - subpopulations 176
 - surface antigen heterogeneity 201–202
 - T cell activation 343–354
 - T cell immunity 4
 - T cell responses 349
 - Th2 responses 1069–1071
 - TLR-mediated activation 411–414
 - tolerance 619–622
 - tolerance induction 569–590
 - tolerogenic 517–648
 - transcriptional profile 185
 - turnover time 15

- DC activation
 - adjuvants 796
 - autoimmune diseases 939–945, 949–950
 - CpG ISS-ODN 796
 - fungi 921–923
 - *Leishmania mexicana* 191
 - modulation 155
 - molecular profile 190–192
 - pathways 298
 - pattern recognition 468–469
 - pro-inflammatory cytokines 182
 - SR 155
 - Systems Biology 468–470
 - *Toxoplasma gondii* 694–698
 - tuning 468–470
- DC activity, regulation 699
- DC and apoptotic cells
 - interaction 602–605
 - peripheral tolerance 603–605
- DC/APC, eye 103–107
- DC-based immune intervention strategies,
 - Leishmaniasis 686–688
- DC-based therapies
 - DC-T Cell interaction 1035–1036
 - DC-Treg inter-relationship 1036–1037
 - future challenges 1035–1038
 - GITR-ligand 1036
 - glucocorticoid-induced TNFR family-related receptor 1036
 - HIV infection 796–797
 - immune system crossroads 1037–1038
 - renal cell carcinoma 1119–1122
 - T cell stimulatory effect 1037
 - T cell tolerance 1025
 - tolerance induction 1035–1038
 - tolerogenic DC fingerprints 1037–1038
- DC biology 1–648
 - HIV infection 777–778
 - scavenger receptors 150–156
- DC conditioning, fungi 923–926
- DC cross-talk 481–516
- DC-CTL immunobiology, systems biology 461–470
- DC-CTL interaction 455–480
 - activating signals 466–468
 - antigen translocation 464
 - communication modes 456
 - co-signaling 465
 - cross-talk 487–490
 - CTL overshoot 465–466
 - DC elimination 464
 - DC recruitment 464
 - DC-lineage concept 467
 - DC/NK cross-talk 487–490
 - effector CTL 464
 - elimination 464
 - feedforward control 465–466
 - immature DC 464
 - immunostimulatory cells 466
 - intrathymic differentiation pathway 467
 - mature DC 464
 - modularity 457–458
 - molecular ‘ping-pong’ interactions 464–465
 - phenotypes 464
 - ping-pong interactions 464–465
 - protocols 457–458
 - rapid signal amplification 464–465
 - recruitment 464
 - redundant activating signals 466–468
 - robust biological system 456
 - signal amplification 464–465
 - signal strength 462
 - signals 466–468
 - spatiotemporal view 469
 - subsets 466–468
 - systems biology 459
 - T lymphocytes 487–490
 - threshold 465
- DC-derived factors, T cell responses 408–411
- DC development 13–72
 - cooperating cytokine signals 36–38
 - cytokine regulation 28
 - DC Subtypes 202
 - Flt3 18–20, 29
 - GM-SCF 29
 - inflammatory stimuli 19
 - interleukin 3 30
 - interleukin 4 30
 - interleukin 15 31
 - pathways 27
 - transcription factor network 53–71
 - transforming growth factor beta-1 32
 - tumor necrosis factor-alpha 32
 - unexpected redundancy 16–17
- DC differences, cytokine environments 396
- DC differentiation 256
 - proposed models 15–16
 - stromal cells 582
- DC-driven virus spread 784
- DC elimination, DC-CTL interaction 464
- DC entry
 - HSV-1 879–885
 - peripheral lymph 282
- DC-epithelial cell interactions 759–772
- DC exit, peripheral tissues 282
- DC expansion, myeloid 36–38

- DC exploitation, transplantation tolerance 997–1002
- DC extraction, enzymatic digestion 280
- DC function
 - activator 694
 - CMV 822
 - HCMV 817–819
 - HSV-1 881–885
 - Langerhans cells 82
 - modulation 416
 - modulation by Mv 866
 - mycobacteria 755
 - parasite evasion 683–684
 - parasitemia 662
 - rodent malaria 661
 - *Schistosoma* eggs 136
 - *Toxoplasma gondii* 703–704
 - tuberculosis 755
- DC generation
 - autoimmune diseases 950–951
 - tolerance induction 1006–1007
- DC hematopoiesis regulation, cytokine signals 33–43
- DC-HIV Interplay 778
- DC in allograft rejection, transplantation tolerance 985–989
- DC in malaria 658–660
- DC in tuberculosis 746
- DC-induced T cell tolerance, tolerance induction 1022–1026
- DC infection
 - HCMV 820–821
 - HIV 776–777
- DC interaction
 - epithelial cells 759–772
 - *Leishmania* parasites 673–676
- DC-lineage concept, DC-CTL interaction 467
- DC maturation 5–6, 124, 346–347, 619–622
 - cancer vaccines 1101–1102
 - DC vaccination 1135
 - eye 102
 - filoviruses 834–835
 - graft rejection 971
 - graft-versus-host disease 975–976
 - HIV infection 787
 - HSV-1 881–882
 - immunity 996–997
 - inhibitors 527
 - measles virus 862–863
 - modulation by Mv 866
 - NF- κ B 55
 - NK cells 485
 - *Salmonella* 723, 730–732, 734–736
 - tolerance induction 1021
 - transcriptoin factors 55
 - virus fate 787
- DC-mediated HIV transmission 789
- DC-mediated immunotherapy, DC vaccination 1129–1130
- DC-mediated NK-cell activation 483–484
- DC migration 279–312
 - autoimmunity 303
 - cancer vaccines 1102–1103
 - cells 295–296
 - control 295–312
 - eicosanoids 303
 - fate 285–286
 - HSV-1 882–884
 - Leishmaniasis 676, 678
 - lymph node 220
 - pathway 299
 - regulating factors 303
 - tuning 303–305
- DC migration factors, graft rejection 971
- DC migration into inflammatory sites, autoimmune diseases 945–946
- DC network, asthma 1061
- DC-NK cells
 - interaction 484–486
 - meeting 484–487
- DC-NK cross-talk 490–493
 - adaptive immunity 487–489
 - bacterial infections 491
 - cancer 491–493
 - CD4⁺CD25⁺ 489–490
 - CML 491
 - conventional T cells 489–490
 - DC-CTL interaction 487–490
 - exosomes 492
 - GIST 491
 - GvHD development 492
 - immunity 487–489
 - infectious diseases 490–491
 - innate immunity 487–489
 - MCMV 490
 - modulation 489–490
 - NK-cell effector functions 492
 - physiopathology 490
 - regulatory T cells 489–490
 - T cells 489–490
 - viral infections 490–491
- DC numbers, SLE 947
- DC phagocytose
 - apoptotic cells 592
 - Leishmaniasis 676
- DC phenotypes
 - modulation 155

- transcription factor knockout mice 58–59
- *see also* DC subsets
- DC polarization 407
- DC populations 385–404
 - dendrogram 631
 - distinct 392
 - flexibility 389–390
 - gene expression patterns 631
 - human 390–392
 - intestinal epithelium 760–762
 - modulated 629–632
 - mouse 388
 - plasticity 385–404
 - relative gene expression patterns 631
- DC precursors 225, 524–525
 - differentiation pathway 466
 - immediate 17
 - MSC 524
- DC priming, indirect 416
- DC progenitor cells, pre-expansion 35
- DC receptors, HIV infection 778
- DC recognition of malignant changes, human cancer 1083–1084
- DC recruitment, DC-CTL interaction 464
- DC regulatory functions, *Toxoplasma gondii* 693–708
- DC relationship to immunodeficiency viruses 773–812
- DC response, schistosome antigen 710–717
- DC-schistosome interaction 187–188
- DC sentinel function, *Toxoplasma gondii* 693–708
- DC-SIGN 131–132
 - ASGPR 844
 - attachment factor 841, 844
 - cancer vaccines 1097
 - DC driven HIV transfer 841
 - DEN interactions with DC 843
 - filovirus infection 842–843
 - filoviruses 841–844
 - HIV 841
 - hMGL 844
 - Jurkat T cell line 842–843
 - Leishmaniasis 673
 - ligation 416
 - mannose-containing carbohydrates 135
 - pathogens portal 841
 - portal for pathogens 841
 - *S. mansoni* 136
 - *Schistosoma* 713
 - siRNA 841
 - transmission 134
 - tuberculosis 747
 - ZEBOV GP harboring pseudotypes entry 842–843
- DC signaling, asthma 1062
- DC-SIGNR 844
- DC sublineage pathway, independent 36
- DC subpopulations 355
 - *Toxoplasma gondii* 694–696
- DC subsets 483–484
 - asthma 1061
 - autoimmune diseases 942–945
 - cancer 1095–1116
 - cancer vaccines 1097–1101
 - circulating 791
 - DC vaccination 1136
 - encounter with *Toxoplasma gondii* 695
 - HIV infection 777
 - *Leishmania* uptake 675–676
 - myeloid 33
 - NK cells 483–484
 - presentation of antigens 428
 - *Salmonella* 724–730
 - TLR 122
 - tolerance induction 1029–1031
 - tolerogenic 522–524
 - transplantation tolerance 990
- DC subtypes 199–218
 - DC development 202
 - functional differences 200, 212
 - generation 210–211
 - infected mice 202
 - lifespan 210–211
 - lineage origin 53
 - lymph node 206–208
 - lymphoid organ 209–210
 - recognition 201–202
 - steady-state versus infected mice 202
 - *see also* DC subsets, DC phenotypes
- DC surface antigen heterogeneity 201–202
- DC-T cell interaction
 - DC-based therapies 1035–1036
 - HIV infection 783–788
- DC-T cell milieu, HIV infection 776, 783–784
 - virus replication 783–784
- DC-T cell mixtures, interaction with HIV 788
- DC-T cell synapses, HIV infection 784
- DC-T cells virus spread, phases 786
- DC-T cell interaction, strength 387
- DC therapy 1031–1033
 - chronic rejection treatment 1033–1034
 - clinical use 1035
 - indirect pathway 1031–1033
 - transplant vascular sclerosis 1033

- vaccination 1136
- DC transcriptome 185
- DC-Treg inter-relationship, DC-based therapies 1036–1037
- DC vaccination 8–9
 - antigen entry routes 1133–1134
 - antigen loading improvement 1136–1137
 - antigen presentation efficiency 1130
 - antigenic cargo 1134–1135
 - cancer 1129–1142
 - clinical vaccination 1136–1137
 - crosspresentation 1130–1131, 1133–1134, 1137
 - C-type lectin receptors 1133
 - cytosol 1134
 - dendritic aggresome-like structures 1135
 - dying cells uptake 1131
 - endosomal compartments 1133
 - exosomes 1133
 - Fcγ receptor
 - fungi 927
 - heat shock protein uptake 1132
 - immune complexes uptake 1131–1132
 - immunotherapy 1129–1130
 - influenza-infected monocytes 1131
 - lectin receptors 1133
 - lysosomal compartments 1133
 - maturation 1135
 - multiple tumor antigens sources 1133
 - opsonized pathogens uptake 1131–1132
 - peptide complexes uptake 1132
 - phagosomes 1134
 - proteasome 1134
 - receptor-mediated uptake 1130–1131
 - regulation of crosspresentation 1135
 - subsets in crosspresentation 1136
 - tumor antigens sources 1133
 - tumor cells uptake 1131–1132
- dead cells 608
- dead cells uptake, tolerance induction 578
- dead end hosts, DEN 835
- DEC-205
 - pharmacologically modified DC 621
 - tolerance induction 572–573, 575
- defective abnormalities in DC
 - autoimmune diseases 947
 - common variable immunodeficiency 947
 - IDDM 947
 - multiple sclerosis 947
 - RA 947
 - Sjögren's syndrome 947
 - SLE 947
 - Wiskott–Aldrich syndrome 947
- defective downregulation, activated DC 942
- defensins, chemotactic factors 302
- delayed type hypersensitivity *see* DTH reactions
- deletion, T cell tolerance 519–520
- deletional mechanism, HCMV 819
- DEN 829, 835–836
 - *Aedes aegypti* 835
 - *Aedes albopictus* 835
 - bystander DC 837
 - dead end hosts 835
 - differential effects 837
 - epidemiology 835
 - flavivirus family 835
 - immature MDSCs 836
 - infected DC 837
 - mosquitoes 835
 - pathology 835
 - progeny virions assembly 836
 - Replication 836
 - serotypes 844
 - targets 844
- DEN interactions with DC, DC-SIGN 843
- dendrite projections, asthma 1061
- dendritic aggresome-like structures, DC vaccination *see* DALIS
- dendritic cells *see* DC
- dendrogram, DC populations 631
- Dengue hemorrhagic fever 836
 - *see also* DEN
- dengue virus *see* DEN
- dermal/interstitial DC 33
- detour pathway, tuberculosis
- development affiliated genes 19
- developmental map, hematopoietic 14
- dextran sulfate, HIV infection 788
- diabetes
 - tumor necrosis factor-alpha 31
 - type I 323
- diacyllipopeptides, TLR2 411
- different DC populations, infection by HSV-1 880
- differential effects, DEN 837
- differential ligand recognition 167
- differential TLR expression 392
- differentially expressed antigens, peripheral blood DC 225
- differentially expressed genes, functional classification 189
- differentiation
 - blood monocytes 262
 - CTL 462–463
 - dendritic cells 343–354
 - effector T cells 345–346
 - LC 39

- monocyte 260–261
 - differentiation inhibition, human cancer 1084–1085
 - differentiation pathway
 - DC precursors 466
 - interferon-producing cells 466
 - intrathymic 467
 - plasmacytoid DCs 466
 - differentiation stages, tolerogenic DC 517–544
 - 1 α ,25-dihydroxyvitamin D₃ *see* VD₃
 - diphtheria toxoid, maleylation 151
 - direct alloantigen presentation, transplantation tolerance 985–986
 - direct alloantigen presentation pathway, graft rejection 968
 - direct allorecognition pathway, immune regulation 1020
 - direct HIV interactions, prevention 788
 - disability-adjusted life years *see* DALY
 - disease, DC 649–1092
 - disease models, CD1d-restricted 328
 - disease pathogenesis, dendritic cells 6–7
 - diseases
 - dendritic cells 7
 - *Leishmania* parasites 670
 - distinct recognition receptors in DC, exploitation by *Candida albicans* 922
 - diversity, functional 323–325
 - division of labor, transplantation tolerance 990
 - DNA, binding proteins 54
 - DNA binding domain, IRF 60
 - DNA binding proteins
 - Kruppel family 54
 - zinc finger 54
 - DNA-positive cells, HIV infection 776
 - DNA viruses, HSV-1 875
 - dominant-negative transcription factors, pDCs in human 224
 - donor bone marrow, transplantation tolerance 999
 - donor cells, early apoptosis 606
 - donor DC, graft-versus-host disease 977
 - donor hematopoietic cell microchimerism, transplant tolerance 1026
 - donor T cell removal 973
 - doses
 - antigen 387
 - tolerance induction 1022
 - double-stranded DNA, recognition 228–229
 - downstream assessment 636–638
 - Drosophila* protein, toll 119
 - dsRNA 436
 - DTH reactions, transplantation tolerance 990
 - dual impact, graft-versus-host disease 973–974
 - dying cells uptake, DC vaccination 1131
 - dysfunctional DC maturation, human cancer 1085
- E**
- E3 gene region, adenovirus 1149
 - EAE, autoimmune diseases 938
 - early hematopoietic progenitor cells, lineage-restricted 14
 - early thymocyte progenitors 15
 - EBI3 *see* Epstein-Barr virus-induced gene 3
 - EBNA1 901–902
 - polarization of CD4⁺ T cell responses 901–902
 - strong Th1 polarization 901–902
 - T cell responses 901–902
 - Th1 polarization 901–902
 - Ebolavirus *see* EBOV
 - EBOV
 - antigen positive DC 832
 - cynomologous macaques 832
 - filoviruses 830
 - IFN α suppression 833
 - key events 833
 - macrophages 832
 - major targets 832
 - monocytes 832
 - open reading frames 831
 - pathogenesis key events 833
 - proliferation of allogenic T cells 833
 - subspecies 830
 - EBV 897–914
 - active immunization 905
 - adoptive T cell therapy 904
 - associated malignancies 902
 - B cells 898, 900
 - crosspresentation 903
 - EBV immune control 901–903
 - heterogeneous affinity 903
 - immune control 898–899, 901–903
 - immune system 903–904
 - immunosuppression 898
 - infection programs 897
 - innate lymphocytes 904
 - latent infection 897
 - lytic infection 897
 - NCR 898
 - NK cell regulation 898
 - oral hairy leukoplakia 898

- proinflammatory cytokine response 903
- stimulation of lymphocyte compartments 899
- T cell immunity 900
- T cell responses 903
- TLR 904
- tonsillar NK cell activation 899
- ECM, tolerance-associated genes 633
- ectoenzyme, CD38 305
- eczema/dermatitis syndrome *see* AEDS
- effector cells 405
 - distinct sub populations 130
 - T cell activation 344
- effector CTL, DC-CTL interaction 464
- effector functions, NKT cells 321–327
- effector phases
 - graft-versus-host disease 974–975
 - immune response 238
- effector T cells
 - activation 406
 - T cell differentiation 345–346
- effector Th-cell populations 385–386
- effector Th2 lymphocytes, asthma 1060
- effector Th2 responses, asthma 1068–1069
- efferent lymph, dendritic cells 4
- EGF-TM7 receptor family 109
- eicosanoids, dendritic cell migration 303
- electroporation 1156–1159
- elimination, DC-CTL interaction 464
- embryogenesis, cell death 430
- embryoid bodies, tolerance induction 1006
- embryonic stem *see* ES cells
- embryonic stem cell-derived DC *see* esDC
- encephalitogenic oligodendrocyte glycoprotein *see* MOG
- endemic β -herpesvirus, HCMV 813
- endocytic exchange mechanism 440–441
- endocytic pathway, classical 436–438
- endocytic receptors
 - DEC-205 572–573
 - tolerance induction 569
- endocytosis
 - adenovirus 1146
 - IC 434
- endogenous antigens
 - presentation 235
 - self-ligands 320
- endogenous HCMV 814
- endogenous IL-10, *Schistosoma* 715
- endogenous male antigen presentation, transplantation tolerance 998
- endoplasmic reticulum 437
 - access 439
- endosomal compartments 320
 - DC vaccination 1133
 - *Leishmania* parasites 675
- endosomal phagosomes, tuberculosis 753
- endosomes 229, 438
- endothelial cells, adhesion 300
- enigmatic CCR2⁺ CX3CR1^{high} monocytes 265–266
- entry receptors, measles virus 857–859
- enveloped viruses
 - HTV 840
 - LV 839
- environmental instruction, cell differentiation 15
- environmental signals, tolerogenic DC 523
- enzymatic digestion, DC extraction 280
- epicutaneous immunization 89
- epidemic
 - DEN 835
 - filoviruses 830–831
 - HIV-1 773–774
 - Leishmaniasis 669
- epidermal Langerhans cells 73–100
- epidermis
 - adult 77–78
 - inflamed 79
- epithelial barrier 759
- epithelial cells
 - asthma 1070
 - intestinal bacteria 762–763
 - Langerhans-type DC 27
 - mucosal 180–182
 - NOD proteins 762
 - PRR 762
 - TLR 762
 - tolerance induction 570
- epithelial infection
 - chemokine CXCL-8 762
 - indicator 762
- epithelial remodeling 1072
- Epstein-Barr Virus *see* EBV
- Epstein-Barr Virus-induced gene 3 408–409
- erythrocytes
 - clonal progenitors 14
 - infection 416
 - *P falciparum*-infected 658
- erythrocytic stage, malaria 654–656
- ES cells
 - anti-inflammatory capacities 412
 - cloning 1007
 - silencing constructs 1006
 - transgenes 1006
 - transplantation tolerance 984, 988
- Escherichia coli* 412
 - expression profile of pathogens 181

- PTX3 167
- ESG 624
- ETP *see* early thymocyte progenitors
- Ets family transcription factor, PU1 56
- eukaryotic initiation factor 5A, CD83 886
- evolutionarily conservation, CD1 molecules 313
- evolutionary selection, cell differentiation 15
- ex vivo tumor vaccination, mouse tumor models 1151–1153
- excitement, DC activation 468–469
- existing immunodeficiency virus infection, therapeutic control 796–797
- exogenous antigens
 - presentation 235
 - protein swapping 509
- exogenous ligands, naturally-occurring 320–321
- exosomal uptake pathway, HIV infection 779
- exosomes 434–435
 - adhesion molecules 501
 - antigen source 502
 - antigen transfer 503
 - B lymphocytes 501–502
 - binding 501–502
 - cell death 503
 - DC vaccination 1133
 - DC-NK cross-talk 492
 - FasL 503
 - fibroblasts 502
 - graft rejection 969
 - heart transplantation model 504
 - HLA 503
 - immune system 502–504
 - interactions 500–501
 - melanoma-derived 503
 - membrane proteins 504
 - messengers 502
 - MHC molecules expression 434
 - MVB 499
 - origin 499–500
 - physiological role 502–504
 - protein destruction 502
 - receptors involved in recognition 431
 - secretion 499–500
 - targets 500–501
 - tumor-cell-derived 503
 - uptake 501–502
 - vector 503
 - vesicle secretion 502
- experimental autoimmune encephalomyelitis *see* EAE
- expressed sequence tag *see* ESG
- expression pattern, TLR 122
- expression profiles 187–188
 - pathogens 181
 - sage software 632
- external maturation, measles virus 863–864
- externalized phosphatidylserine 595
- extracellular Ag, apoptotic cells 592
- extracellular matrix protein *see* ECM
- extracellular signal-regulated kinases, fungi 922
- extraction of DC, lymphoid tissue 203
- extravasation, monocytes 268
- eye
 - anatomy 102
 - anterior chamber 101
 - APC 101–118
 - AqH 103, 106
 - arc of tolerance 108
 - DC maturation 102
 - dendritic cells 101–118
 - immune reflex 108
 - immunoregulatory process 104
 - MHC Class II+ DC 105
 - peripheral tolerance process 104
- F**
- F4/80 protein, ACAID 109
- FACS *see* fluorescence associated cell sorting
 - analysis 205
- factors, T cell response 408–411
- facultative intracellular parasites, tuberculosis 747
- FAE, intestinal epithelium 759
- FasL
 - exosomes 503
 - transplantation tolerance 1001
- Fcγ receptor, DC vaccination
- Fc receptors 433
 - intestinal bacteria 761
 - malaria 658
 - tolerance induction 578–579
- FcR *see* Fc receptors
- feedback control 458–460
 - systems biology 463
- feedforward control, DC-CTL interaction 465–466
- FEEL 150
- female fertility, PTX3 166
- FHA *see* filamentous haemagglutinin
- fibroblasts, exosomes 502
- filamentous haemagglutinin 416

- filarial nematode glycoprotein ES-62, Th-cell responses 390
- filovirus 829–835
 - aberrant DC maturation 833–834
 - concentration 844
 - cytokines secretion 833
 - DC maturation 834–835
 - DC-SIGN 841–844
 - EBOV 830
 - epidemiology 830–831
 - hemorrhagic fever 830
 - infections 831
 - late domain 831
 - liver 844
 - lymph nodes 844
 - MARV 830
 - pathology 830–831
 - proteins 834–835
 - replication 831
 - secretion 833
 - tissue factor secretion 833
 - tropism 832
 - Vero cell line 833
 - VLP 834
- first generation vectors, adenovirus 1146
- FL binding 29
- flagellin, receptor 119
- flavivirus family, DEN 835
- flexibility, DC populations 389–390
- flexible DC Th-cell development 388–392
- Flt3 3
 - ligand injection 18
 - receptor 18, 28
 - working model 18–20
- Flt3 ligand 27–29, 224
 - DC development 29
 - knock out phenotype 29
 - phenotype 29
 - signal transduction 29
 - transmembrane protein 28
- fluorescence activated cell sorter 89
- fluorescence associated cell sorting 13
- follicle-associated epithelium *see* FAE
- follicular DC 279
- foreign antigen specific T cells, autoimmune diseases 937
- foreign pathogens, discrimination 181
- fully mature DC 531
- function suppression, human cancer 1086–1087
- functional consequences, MV-DC interaction 860–862
- functional differences, DC subtypes 212
- functional diversity, NKT cells responses 323–325
- functional impact, tolerance associated 638
- functional modification, DC 790–793
- functional phenotype, DC 620
- functional plasticity
 - cell differentiation 15
 - DC 229
 - pDCs-IPCs 234
- functional relevance, tolerance candidates 637
- functional role for DC, asthma 1068–1069
- functional TRAIL, measles virus 864
- functional transgenic protein, lipofection 1159
- fungal morphotypes, murine DC
 - phagocytosis 919
- fungal recognition 918–918
 - human DC 918
- fungal vaccines
 - fungal vaccines 927–928
 - HSCT 927
- fungi 915–934
 - *A. fumigatus* 918
 - adaptive immune response 916
 - AIDS 925
 - antigen specific proliferation 926
 - anti-inflammatory state 924
 - *Aspergillus fumigatus* 918
 - bidirectional signaling 925
 - *Candida albicans* 915, 918
 - candidiasis 924
 - coiling phagocytosis 918
 - collectins 923
 - co-stimulation 921
 - *Cryptococcus* 919
 - *Cryptococcus neoformans* 918, 926
 - DC activation 921–923
 - DC conditioning 923–926
 - DC vaccination 927
 - extracellular signal-regulated kinases 922
 - *Histoplasma capsulatum* 918, 922
 - host–parasite interaction 915
 - human DC 918
 - immunity 916–917
 - inflammatory state 924
 - innate response 916
 - lectin-like pathway 920
 - *Malassezia* 925
 - *Malassezia furfur* 918
 - MAPK 921
 - morphological transition 915
 - opsonins 923–924
 - opsono-dependent pathways 920

- PAMP 916
- Peyer's patches DC 923
- protective immunity 916
- PRR 916
- receptor cooperativity 918–918
- receptor exploitation 922
- *Saccharomyces cerevisiae* 918
- signal transduction events 921
- signaling pathway 918
- T cell ligands 925–926
- T cell response 916
- Th1 cells 926–927
- Th2 cells 926–927
- Treg cells 926–927
- tryptophan metabolic pathway 924–925
- vaccinating ability 925
- fungus-associated information translation 926–927
- future challenges, DC-based therapies 1035–1038

G

- α -GalCer, immune responses 324–327
- GALT 759–760
- gamma-activated sequence 61
- gap junctions 441
- GAS *see* gamma-activated sequence
- gastro-intestinal stromal tumors *see* GIST
- GATA-3, Th-cell responses 386
- gene expression
 - DC populations 631
 - tolerance associated 629–632, 636–637
- gene identification, tolerance-associated genes 630
- gene profiling 177–179
 - dendritic cells 175–198
 - pharmacologically modified DC 622
 - technologies 623
- gene transfer
 - adenovirus 1148–1151
 - therapeutic vaccination 1145–1153
- generation, tolerogenic DC 518
- generation of Treg cells, T cell tolerance 1024
- genes
 - differentially expressed 189
 - tolerance-associated 619–648
- genetic background, Th-cell responses 388
- genetic engineering, tolerance induction 1028–1029
- genetic manipulation, DC 637
- genetic modification, transplantation tolerance 1001–1002
- genome structure, adenovirus 1147

- genomic RNA, HTV 840
- genotypes, measles virus 856–857
- Gfi1 *see also* growth factors, 64–65
- GFP-expressing bacteria, *Salmonella* 731
- Ghon complex, tuberculosis 746
- Giemsa staining, pDCs-IPCs 223
- GIST, DC-NK cross-talk 491
- GITR-ligan, DC-based therapies 1036
- global HIV-1 epidemic, viruses 773–774
- global technologies, IL2 production 179–180
- globule protein, apoptotic cells 598–599
- glucocorticoid-induced TNFR family-related receptor, DC-based therapies 1036
- glycan modifications, DCs 134–136
- glycolipid 314
 - antigens 314
 - HIV binding 789
 - lipid transfer proteins 316
 - presentation 315
 - TCR 315–316
- glycoproteins
 - apoptotic cells 595
 - trimeric type ii 143
- glycosylated self-antigens, recognition 131
- glycosylation 131
 - HIV binding 789
 - mouse macrosialin 149
- GM-CSF *see* granulocyte-macrophage colony-stimulating factor, 16, 29, 39–43
 - asthma 1060
 - cytokine family 29
 - DC development 29
 - knock out phenotype 29
 - receptor 29
 - renal cell carcinoma 1118
 - signal transduction 29
- GMP *see* granulocyte macrophage progenitor
- gold-specific T cells, CHS 1050
- gold standard method, cancer vaccines 1101
- Golgi apparatus 437
- β 2-GPI *see* glycoproteins
- graft cells apoptosis, graft rejection 971
- graft-infiltrating DC, immune regulation 1019
- graft rejection 967–982
 - adaptive immunity 972–973
 - alloantigen presentation 969–971
 - alloantigen recognition 967–970
 - allograft rejection 967
 - allorecognition pathways 968
 - APC location 970

- apoptosis 971
 - chemerin 972
 - co-stimulation 968
 - DC maturation factors 971
 - DC migration factors 971
 - exosomes 969
 - immunity links 972–973
 - indirect alloantigen presentation pathway 968
 - inflammatory cytokines 971
 - innate immunity 972–973
 - ischemia 971–972
 - liver allografts 971
 - MHC 967
 - necrotic cell death 971
 - organ ischemia 971
 - oxidative cellular stress 971
 - pathways 967–970
 - reperfusion injury 971–972
 - TLR signaling 972
 - graft-resident DC, immune regulation 1019
 - graft-versus-host disease 967–982
 - alloantigen presentation 973–977
 - bone marrow transplantation 973
 - DC 974–977
 - dual impact 973–974
 - effector phases 974–975
 - hematopoietic cells transplantation. 973
 - initiation phase 974–975
 - irradiation 975
 - pDC recovery profile 976
 - recipient conditioning 975–976
 - signaling pathway 976
 - T cells 973–974
 - graft-versus-leukemia 973–974
 - Grammomys surdaster*, malaria 653
 - granulocyte development, CEPB α 57
 - granulocyte macrophage colony-stimulating factor *see* GM-CSF
 - granulocyte macrophage progenitor 260
 - granulocytes, clonal progenitors 14
 - granulocytic transcription factor, PU1 activity 56
 - granuloma, tuberculosis 746
 - growth factors 27–51, 64
 - epidermal 815, 1072
 - epidermal 598
 - eye 105
 - hematopoietic 551
 - monocytes 260
 - myobacteria 747
 - PTX3 168
 - scavenger receptors 149, 155
 - tolerance induction 519, 1006
 - transforming 672, 885, 1072
 - gut, intestinal epithelium 760–762
 - gut-associated lymphoid tissue *see* GALT
 - gut-homing T cells imprint, mucosal DC 763
 - GvHD *see* graft-versus-host disease
 - GvHD development, DC-NK cross-talk 492
 - GVL *see* graft-versus-leukemia
- ## H
- HAART, HIV infection 791
 - half-life, circulating monocytes 267
 - Hantavirus* *see* HTV
 - hapten, CHS 1047
 - hapten-like Ni epitopes, CHS 1049–1050
 - hapten-peptide determinants, CHS 1048
 - HCMV *see also* MCMV, CMV, 813
 - alloreactive T cell stimulation 818
 - birth defects 813
 - bone marrow progenitors 815
 - CD4+ T lymphocytes defect 813
 - DC function 817–819
 - DC infection 820–821
 - deletional mechanism 819
 - endemic β -herpesvirus 813
 - entry 816–817
 - HSV-1 883
 - IE1 antigen 817
 - IL-10 820
 - immature DC function 817–818
 - immunostimulatory capacity of DCs 818
 - immunosuppression 813–814, 820
 - Langerhans-type DC 819
 - latency 814–815
 - latency associated proteins 814
 - lymphopenia 814
 - maturation 818–819
 - monocytes 814–815
 - mouse model 820–821
 - myeloid lineage 814–815
 - NK cell activity 820
 - potential target cells 815–816
 - replication 816–817
 - strains 816
 - susceptibility 816
 - T cell stimulation 818
 - T cellular immunosuppression 813
 - virus replication 819
 - HDM-sensitive asthmatic 1071
 - heart graft survival 1033
 - heart transplantation model, exosomes 504
 - heat shock proteins 432
 - CHS 1052–1053
 - DC vaccination 1132

- human cancer 1083
- receptors involved in recognition 431
- Helicobacter pylori* 135, 415
- mannose-containing carbohydrates 134
- helix-loop-helix, transcription factors 63
- hematopoiesis 65
- hematopoietic
 - developmental map 14
 - lineage 3
 - progenitor cells 18–20, 33
 - stem cells 14
- hematopoietic cells transplantation., graft-versus-host disease 973
- hematopoietic cytokines, early-acting 33
- hematopoietic lineages
 - dendritic cells 3
 - development 63
- hematopoietic progenitor cells
 - cell development 18–20
 - *in vitro* 33
 - LC differentiation 41
 - lineage-restricted 14
- hematopoietic progenitor/stem cells 39
- hematopoietic stem cells 13–14, 53
 - transplantation tolerance 999
- hemorrhagic fever, with renal syndrome *see* HFRS
 - *see also* filovirus
- hemorrhagic fever viruses *see* HFV
- hemozoin
 - malaria 657
 - toll-like receptors 120
- heparan sulfate proteoglycans *see* HSPG
- hepatitis C virus 415
- Hepatitis* virus, pathogen recognition 125
- herpes family, toll-like receptors 120
- Herpes genitalis*, HSV-1 878
- Herpes labialis*, HSV-1 878
- Herpes simplex* virus *see also* HSV
 - 85, 349
 - type 1 *see also* HSV-1
- Herpes simplex* virus vectors, adenovirus 1149
- Herpesviridae* family, HSV-1 883
- γ-herpesvirus 897
- heteroclitic peptides, cancer vaccines 1104
- heterodimerization, toll-like receptors 119
- heterogeneity
 - cellular 43
 - monocytic cells 261
- heterogeneous affinity, EBV 903
- heterogeneous redundancy, systems biology 460
- HEV 487
- HFRS, HTV 840
- HFV 829–854
- high capacity adenovirus vectors 1147
- high cell turnover, human cancer 1083
- high endothelial venules, plasmacytoid DC migration 297
- high mobility group box 1 protein *see* HMGB-1
- Histoplasma capsulatum*, fungi 918, 922
- HIV
 - binding receptors 778–780
 - blocking mucosal infection 793–794
 - circulating DC subsets 791
 - cytotoxic T lymphocyte response 455
 - DC infection 776–777
 - DC-SIGN 841
 - epidemic 773–774
 - glycosylation 789
 - immunodeficiency 777–778, 783–784
 - infected people 773
 - infectious virus transmission 783–789
 - internalization 782
 - targets 239
 - trans-receptor 133
 - virus-carrying immature DCs 792–793
 - virus-DC-SIGN interactions 133–134
- HIV co-infection 792
 - Leishmaniasis 669
- HIV infection 774–776
 - aldrithiol-2 792
 - anti-envelope antibodies 789
 - antiviral actions 795
 - AT-2 viruses 792
 - carrageenans 788
 - CD209-dependence 783
 - chemoattractants 794
 - chemokine receptor tropism 778
 - co-receptor 776
 - DC biology changes 777–778
 - DC involvement 774–776
 - DC maturation 782, 787
 - DC receptors 778
 - DC subsets 777
 - DC-based therapeutic control 796–797
 - DC–T cell milieu 776, 783–784
 - DC-to-T cell transmission 783–788
 - dextran sulfate 788
 - DNA-positive cells 776
 - entrapment 776
 - exosomal uptake pathway 779
 - functional modification of DC 790–793
 - HAART 791
 - HSPG 779
 - HSV 792

- immature DC 782, 792–793
- immune dampening 792
- immunity boost 794–797
- immunostimulatory capacity 777
- lymphoid tissues 777
- macaque studies 776–777
- mature DC 782
- matured moDC 780
- microbicide strategies 793
- mucosal DC 776–777
- mucosal surfaces 774
- mucosal tissues 777
- nef gene 783
- neutralizing anti-envelope antibodies 789
- onset 774–776
- pDC numbers 777
- potential cellular targets 774
- R5 HIV isolates 793
- receptors expression by DC 778–780
- resistance 780
- RNA-positive LCs 776
- SIV macaque system 776
- spread 774–776
- sulfated polysaccharides 793
- synapses crossing 784
- T cell responses 792–793
- Tat 790
- tenofovir 793
- therapeutic control 796–797
- vaccine strategies 793
- viral vectors 794
- virus amplification 776
- virus movement 784
- Vpr 790
- HIV Infection of DC 780–782
- HIV interactions, prevention 788
- HIV particles, internalization 782
- HIV transmission 789
- HIV vaccines
 - canarypox vectors 795
 - preventative 795–796
 - primary responses 795–796
 - strategies 793
- HIV/SIV vaccination, adenovirus 1153
- HLA, exosomes 503
- HLA-restriction, CHS 1048–1049
- HLA-restriction pattern, therapeutic vaccination 1143
- HLADR⁺ CD14⁺ CD16⁻ monocytes, surface phenotype 263
- HLH *see* helix-loop-helix
- HLH transcription factors, dominant negative antagonists 63
- HMD, CHS 1053
- HMGB-1
 - apoptotic cells 608
 - human cancer 1082
- hMGL, DC-SIGNR 844
- homeostasis
 - CLR 130–131
 - intestinal epithelium 764–766
 - Langerhans cells 77–78
- homing receptors, imprinting 349
- homodimerization, fl binding 29
- homogeneous redundancy, systems biology 460
- homotypic synapses, protein transfer 505
- host DC 974–977
 - graft-versus-host disease 974–976
- host-parasite interactions, fungi 915
- host-pathogen interactions, gene profiling 175–198
- host receptors, *Toxoplasma gondii* 696–698
- host/fungi interface 917–926
- house dust mite *see* HDM-sensitive asthmatic
- HSA, CHS 1051
- HSC *see* hematopoietic stem cells
- HSC generation, immune intervention 1005–1006
- HSCT, fungal vaccines 927
- HSP *see* heat-shock proteins
 - antigenic specificity 154
- HSPG, HIV infection 779
- HSV *see* *Herpes simplex* virus
 - HIV infection 792
- HSV-1 *see* *Herpes simplex* virus-1, 361, 875–896
 - antigen presentation 884
 - antiviral immune responses 880
 - CD83 885–888
 - cell entry 875, 879–880
 - cell surface molecule CD83 885–888
 - crosspresentation 881
 - DC entry 879–885
 - DC functions 881–885
 - DC maturation inhibition 881–882
 - DC migration 882–884
 - DNA viruses 875
 - HCMV 883
 - *Herpes genitalis* 878
 - *Herpes labialis* 878
 - *Herpesviridae* family 883
 - IE-gene products 876
 - immune responses 877
 - induction 877
 - infection 878–879
 - ligands for cell entry 879–880

- mRNA processing 886–887
 - nucleocapsids 878
 - prevention 877
 - receptors for cell entry 879–880
 - replication 876, 878–879
 - T cell stimulation 884–885
 - TAP blocking 884
 - tegument proteins 878
 - type I interferon release 881
 - viral immediate-early proteins 875
 - HSV-2 infection 792
 - HTV 840–841
 - bunyavirus family 840
 - cellular entry 840
 - enveloped viruses 840
 - genomic RNA 840
 - HFRS 840
 - MDDC infection 840
 - pathogenesis 840
 - pulmonary syndrome 840
 - renal syndrome 840
 - *sin nombre* 840
 - huFlt3, expression 19
 - human
 - allogeneic T cells 391
 - APC 234
 - blood DC 225
 - dendritic cell populations 390–392
 - pDCs-IPCs 231–233, 239
 - pentraxin superfamily 166
 - peripheral blood DC 225
 - human asthma 1071–1072
 - human cancer 1081–1092
 - abundant cell population 1085
 - antigen-specific T cells 1082
 - chemokines 1085
 - danger signals 1082
 - DC recognition of malignant changes 1083–1084
 - differentiation inhibition 1084–1085
 - dysfunctional DC maturation 1085
 - function suppression 1086–1087
 - heat shock proteins 1083
 - high cell turnover 1083
 - HMGB-1 1082
 - ImC 1085
 - immunity 1082
 - malignant changes in tissues 1083–1084
 - maturation inhibition 1084–1085
 - migration 1085–1086
 - MUC1 1083, 1086
 - necrotic cells 1083
 - post-translationally modified proteins 1083
 - stress proteins 1083
 - tumor immunity 1081
 - VEGF 1085
 - human cytomegalovirus *see* HCMV
 - human DC
 - antiviral immune responses 429
 - fungal recognition 918
 - fungi recognition 918
 - IL-12 production 231–233
 - lipofection 1159
 - myelomonocyte surface antigens 36
 - necrotic tissues 429
 - human DC activation, *Toxoplasma gondii* 698
 - human DC subsets, cancer vaccines 1098
 - human DC subtypes 211–212
 - human dendritic cell populations 390–392
 - human immunodeficiency virus *see* HIV
 - human leukocyte antigen *see* human leukocyte antigen
 - human malaria, DC 658–659
 - human metastatic renal cell carcinoma, clinical studies 1121
 - human monocyte-derived DC, *Schistosoma* 713
 - human monocyte subset, phenotype 263
 - human pDCs-IPCs, IL-12 production 231–233
 - human peripheral blood DC 225
 - human serum albumin *see* HSA
 - human T cells, nickel presentation 1048–1051
 - humoral immunity
 - cancer 1095
 - malaria 655–656
 - humoral innate immunity 165–174
 - Hyper-IL6 35
 - hyperacute rejection, transplantation tolerance 983
 - hypersensitivity 361
 - hyporesponsiveness, T cell tolerance 519
- I**
- IC, endocytosis 434
 - ICOS signaling, T cell activation 345
 - Id2 63–64
 - IDDM
 - autoimmune diseases 938
 - defective abnormalities in DC 947
 - IDO 1086
 - asthma 1066
 - transplantation tolerance 992–993
 - IE-gene products, HSV-1 876
 - IE proteins 876

- IE1 antigen, HCMV 817
- IFN
- T cells differentiation 386
 - *see also* interferon, type I interferon
- IFN α 235
- modulation 393–395
 - pDCs-IPCs 230–231
 - systemic lupus erythematosus 239
- IFN α driven disease, autoimmune diseases 941
- IFN α production, TLR7/TLR9-mediated 231
- IFN α protein 230
- IFN α suppression, EBOV 833
- IFN α/β , cytokines production 356
- IFN β , positive feedback 230–231
- IFN γ
- producing cells 483
 - Th-cell responses 393
- IFN γ cytokines 405
- IFN γ production 358
- IFN γ synthesis, *Toxoplasma gondii* 693
- IFN family 409
- IFN producing cells
- pDCs-IPCs 229–230
 - transplantation tolerance 991
- IFN receptors, type 1 230–231
- IFN responses, pDCs-IPCs 229
- IFNAR *see* type I IFN receptor
- IFNGR *see* type II IFN receptor
- IFNs, type 1 221
- Ig-secreting B cells 360
- IgE 30
- IgE-mediated type I allergy 1047
- IgM antibodies, apoptotic cells 597
- ignorance, T cell tolerance 519
- Ikaros* 54–55
- mutation 55
- IL-1 360
- IL-1 α mRNA, increased expression 361
- IL-1 secretion by *in vivo* 362
- IL-1 superfamily, cytokines production 359
- IL-10, HCMV 820
- IL-10 gene, transplantation tolerance 1001
- IL-10 production, *Schistosoma* 713
- IL-12 235
- cytokines production 357–358
 - Leishmaniasis 672
 - production 233, 393
- IL-12 production, human pDCs-IPCs 231–233
- IL-12 production by DC, Leishmaniasis 681
- IL-12p70, cell-promoting factors 408
- IL-12p70 production, modulation 393–395
- IL-15 *see* interleukins
- IL-18, cytokines production 359
- IL-2 gene expression 183
- IL-2 production 179–180
- IL-23, cytokines production 357–358
- IL-27, cytokines production 357–358
- IL-3 *see* interleukins
- IL-4 *see* interleukins, 410
- cancer vaccines 1100
- IL-6 360
- ag processing 943
- IL10 production 837
- IL15-DC, cancer vaccines 1101
- ILT
- pharmacologically modified DC 622
 - tolerance induction 580–581
- ImC, human cancer 1085
- imidazolquinoline peptides 413
- immature DC 485, 525–528
- anergy 525
 - DC-CTL interaction 464
 - HCMV 817–818
 - HIV infection 792–793
 - HIV internalization 782
 - immune regulation 1018
 - inhibitors 526
 - maturation inhibitors 526
 - maturation resistance 526–530
 - resistance 526–530
 - T cell anergy 525
 - transplantation tolerance 994–996
 - tumor- infiltration 240
- immature MDDCs
- DEN 836
 - LV 839
- immature myeloid cells *see* ImC
- immature/steady state DCs, autoimmune diseases 938
- immediate-early-1 *see* IE1 antigen
- immediate-early proteins *see* IE proteins
- immune balance, T cell tolerance 520
- immune cells
- development 60
 - protein transfer 506–508
 - regulation 238
- immune complexes 433–434
- DC vaccination 1131–1132
 - receptors involved in recognition 431
- immune control 901–903
- EBV 899
- immune dampening, HIV infection 792
- immune deviation
- anterior chamber 106
 - T cell tolerance 520

- immune effector cells 321
- immune effectors, cancer vaccines 1106
- immune homeostasis, intestinal 764–766
- immune hosts, Leishmaniasis 680
- immune induction, Leishmaniasis 676
- immune intervention strategies
 - CRT 1005–1007
 - Leishmaniasis 669–692
- immune modulating APC, tuberculosis 750
- immune molecules, Langerhans cells 75
- immune polarization, *Toxoplasma gondii* 700
- immune reactivity, fully mature DC 531
- immune recognition, malaria 656
- immune reflex, eye 108
- immune regulation 1017–1046
 - allograft rejection 1017
 - allorecognition pathways 1020
 - APC 1017
 - cell surface receptors 1018
 - danger theory model 1019
 - direct allorecognition pathway 1020
 - graft-infiltrating DC 1019
 - graft-resident DC 1019
 - immature DC 1018
 - indirect allorecognition pathway 1020
 - inflammation 1019
 - lung 1064
 - pathways of allorecognition 1020
 - T cells 1020
 - tolerance induction 1021
- immune response 177, 238
 - antigen specific 53
 - asthma 1062–1065
 - autoimmune diseases 943
 - cancer vaccines 1099–1100
 - CMV 822
 - CRT 1005–1007
 - determination 124–128
 - EBV 906
 - effector phase 238
 - fungi 916
 - α -GalCer-activated cells 325–327
 - generation 357
 - HSC generation 1005–1006
 - *Leishmania*-specific 676
 - malaria 654
 - memory phase 238
 - mixed chimerism 1005
 - modulation 325–327
 - modulators 129–140
 - pDCs-IPCs 233–238
 - polarization 358
 - regulation 233–238, 680–683
 - *Schistosoma* 711
 - *Toxoplasma gondii* 693–708
 - transplantation tolerance 996
 - tuberculosis 749
- immune serum, malaria 655–656
- immune system
 - complexity 177–179
 - DC 175
 - DC-based therapies 1037–1038
 - dendritic cells 175
 - EBV detection 903–904
 - exosomes 502–504
 - negative control 619
 - presentation 151
 - protein swapping 508–509
 - systems biology 460
 - tuberculosis 746
- immune tolerance, cancer vaccines 1100
- immunity 4
 - autoimmune diseases 935, 950
 - balance 608
 - cell-mediated 385
 - DC maturation 996–997
 - DC-NK cross-talk 487–489
 - dendritic cells 182–183
 - functional modification of DC 790–793
 - fungi 915–917
 - graft rejection 972–973
 - HIV infection 794–797
 - human cancer 1082
 - *in vivo* induction 85–86
 - induction 574–575, 577
 - Langerhans cells 85–86
 - malaria 654
 - *Salmonella* 723
- immunization, cancer vaccines 1102
- immunochip 636–637
- immunodeficiency 773–812
 - HIV 777–778, 783–784
 - therapeutic control 796–797
 - *Toxoplasma gondii* 693
- immunogenicity
 - *in vitro* generation 151–152
 - renal cell carcinoma 1121
- immunoglobulin-like transcript *see* ILT
- immunoglobulins, Fc receptors 579
- immunological efficacy, cancer vaccines 1106–1107
- immunological tolerance 53
- immunologically quiescent monocytes, autoimmune diseases 941
- immunology, dendritic cells 6
- immunomodulatory functions, activated NKT cells 326

- immunoreactivity, T cell tolerance 520
- immunoreceptor tyrosine-based activation motifs *see* ITAM
- immunoregulatory process, eye 104
- immunoregulatory role, NKT cells 328
- immunostimulatory capacity, HIV infection 777
- immunostimulatory capacity of DCs, HCMV 818
- immunostimulatory cells, DC-CTL interaction 466
- immunostimulatory context, human cancer 1082
- immunosuppression
 - APC modulation 111
 - CD83 887
 - EBV 898
 - HCMV 813–814, 820
 - measles virus 855
 - tolerance induction 1032
- immunosurveillance
 - dendritic cells 183
 - NK cells 481
 - renal cell carcinoma 1117–1118
- immunotherapy, cancer 88, 1095
 - DC vaccination 1129–1130
 - dendritic cells 7–8
 - EBV 904–905
 - electroporation 1158
 - Langerhans cells 88–89
 - Leishmaniasis 685–686
 - renal cell carcinoma 1118–1123
- impairment, migratory activities 684
- imprinting
 - homing receptors 349
 - tissue homing receptors 349
- in vitro* DC hematopoiesis, regulation 33–43
- in vitro*-generated DC 356
- in vitro* generation, SR ligands 151–152
- in vivo* differentiation, DC 256
- incomplete signals, pharmacologically modified DC 621
- indirect alloantigen presentation, transplantation tolerance 986–987
- indirect alloantigen presentation pathway, graft rejection 968
- indirect allorecognition pathway, immune regulation 1020
- indirect pathway
 - DC therapy 1031–1033
 - tolerance induction 1002–1004
- indirect priming of DC 416
- Indoleamine 2,3-dioxygenase *see* IDO
- inducible nitric oxide synthase *see* iNOS
- induction
 - HSV-1 specific immune responses 877
 - tolerance 569–590
- infected DC
 - DEN 837
 - *Salmonella* 727
- infected iRBC 659
- infected mice, DC subtypes 202
- infected people, HIV-1 773
- infection 230
 - cytokines 355
 - cytomegalovirus 813–828
 - EBV 897
 - HSV-1 878–879
 - monocytes contribution 259–260
 - monocytes recruitment 268–269
 - self-limitation 441
 - sensors 183–185
- infection cycle, adenovirus 1148
- infectious diseases
 - DC-NK cross-talk 490–491
 - dendritic cells 6
 - vaccines 8–9
- infectious virus transmission, HIV 783–789
- inflammation 253, 1059
 - apoptotic cells 592
 - chemotactic stimuli 301
 - immune regulation 1019
 - macrophages 253
 - monocytes contribution 259–260
 - monocytes recruitment 268–269
 - NK cells 486
- inflammatory chemokines 296
 - Leishmaniasis 677
 - receptors 296
- inflammatory conditions
 - Langerhans cells 78
 - Lox-1 148
 - migraton control 297
- inflammatory cytokines 124
 - graft rejection 971
- inflammatory molecules, Th-cell responses 391
- inflammatory monocytes, CCR2 + CX3CR1 low 264
- inflammatory response, intestinal bacteria 763
- inflammatory signals
 - malaria 657
 - primary 168
- inflammatory sites, autoimmune diseases 945
- inflammatory state, fungi 924

- inflammatory stimuli, DC development 19
- inflammatory T cell responses, priming 348
- inflammatory Th2 cells 7
- inflammatory TLR ligands, *Schistosoma* 714
- influenza infected monocytes, DC vaccination 1131
- influenza virus, crosspresentation 440
- Influenza virus vectors, adenovirus 1149
- inhaled antigen, asthma 1062–1065
- inhibiting dc-driven infection 788–789
- inhibitors
 - DC maturation 527
 - DNA binding/differentiation) transcription factor family 63
 - immature DC 526
- inhibitory cytokine TGF- β , T cell differentiation 346
- inhibitory cytokines, *Salmonella* 731
- inhibitory mechanisms, pathogen recognition 125
- inhibitory molecules, tolerance induction 580–581
- inhibitory monoclonal antibodies, marco 145
- inhibitory motifs *see* ITIM
- inhibitory pathways 345
- inhibitory receptor, NK cells 485
- initiation phase, graft-versus-host disease 974–975
- iNKT cell 107
- innate immunity 132, 182–183, 230
 - autoimmune diseases 935
 - DC-NK cross-talk 487–489
 - dendritic cells 165–174
 - graft rejection 972–973
 - human cancer 1082
 - humoral arm 166
 - PTX3 170–171
- innate lymphocytes, EBV 904
- innate response 180–182
 - fungi 916
 - pDCs-IPCs 228–233
- iNOS
 - Leishmaniasis 671
 - *Salmonella* 725
- insulin-dependent diabetes mellitus *see* IDDM
- intDC *see* interstitial/dermal DC (intDC)
- Integrins, apoptotic cells 596, 607
 - tolerance induction 577–578
- interactions
 - apoptotic cells 591–618
 - between DCs and HIV viruses 788
 - DC and apoptotic cells 602–605
 - DC and NK cells 484–486
 - DC with *Salmonella in vivo* 733–737
 - DC-epithelial cell 759–772
 - dynamics 185
 - exosomes 500–501
 - molecular profile 190–192
 - pathogens with DC 132
 - virus-DC-SIGN 133–134
- intercellular communication 499–516
- intercellular transfer, membrane proteins 507
- interface between innate and adaptive immunity, fungi 917
- interferon 385
 - type 1 221
 - type I 356–357
- interferon-producing cell development
 - Flt3-license 18–20
 - unexpected redundancy 16–17
- interferon-producing cell differentiation, proposed models 15–16
- interferon-producing cell precursors 17
- interferon-producing cells 349
 - bone marrow progenitors 13
 - differentiation pathway 466
 - turnover time 15
 - type 1 13, 219–252
- interferon regulatory factor 60
- interferon stimulated response elements 61
- interleukins 30–31
- intermediate contact sites, CHS 1053
- intermediate precursors, isolation 16
- intermediates, monocyte 40
- internalization
 - apoptotic cells 604
 - CLRs on DC 133
 - fl binding 29
 - HIV particles 782
 - *Salmonella* 724–727
- interphotoreceptor retinoid binding protein 303
- interstitial/dermal DC (intDC) 27
- intestinal, immune homeostasis 764–766
- intestinal bacteria 759–772
 - antigen entry 760
 - bacteria cells 762–763
 - bacterial uptake 761
 - cross-talk 762–763
 - epithelial cells 762–763
 - inflammatory response 763
 - mechanisms of bacterial uptake 761

- pathogenicity 760
- PPAR- γ 763
- T cells relocation 763
- intestinal DC, transport 286
- intestinal epithelium 759
 - antibodies production 760
 - antigen uptake 760–762
 - antimicrobial peptides 759
 - bacterial handling 766–767
 - cell derived factors 766
 - cross-talk between ECs and DCs 764–767
 - DC populations 760–762
 - FAE 759
 - gut 760–762
 - homeostasis regulation 764–766
 - intestinal immune homeostasis 764–766
 - lamina propria 759
 - lymphoid follicles 760
 - M cells 759
 - MLN 760
 - mucosal immune responses 760
 - mucous glyocalix 759
 - Peyer's patches 759
 - *Salmonella* 733–734
 - soluble antigens 760
 - tight junctions 759
 - type-1 reovirus 766
- intestinal immune homeostasis, intestinal epithelium 764–766
- intra-ocular fluids 103
- intracellular pathogens, tuberculosis 747–748
- intracellular routing, carbohydrate-recognizing CLRs 129
- intracellular TLR-7, pDCs-IPCs 228–229
- intracellular trafficking pathway 314
- intrathymic differentiation pathway, DC-CTL interaction 467
- IPC *see* interferon-producing cells, 221
- iRBC, malaria 656
- IRBP *see* interphotoreceptor retinoid binding protein
- IRF *see* interferon regulatory factor
 - DNA binding domain 60
- IRF family, factor 60–63
- irradiation, graft-versus-host disease 975
- ischemia, graft rejection 971–972
- isoforms, ikaros 54
- isolation, pDCs-IPCs 222–224
- ISRE *see* interferon stimulated response elements
- ITAM 572
- ITIM 572

J

- JAK *see* Janus kinase
- Janus kinase 29–30
- Jurkat T cell line, DC-SIGN 842–843

K

- kala-azar, Leishmaniasis 670
- key cytokines 28–32
 - IL-12 386
- key events, EBOV pathogenesis 833
- kidney tumor, renal cell carcinoma 1118
- killer cells
 - crosstalk to DC 481–498
 - Ig-like receptors 318
- killer DC, transplantation tolerance 1001
- KIR *see* killer cells
- knock out phenotype, Flt3 ligand 29
- knock out phenotype:
 - GM-CSF 29
 - interleukin 4 30
 - interleukin-15 31
 - transforming growth factor beta-1 32
 - tumor necrosis factor-alpha 32
- Kruppel family, DNA binding proteins 54

L

- lactadherin, apoptotic cells 598–599
- LAK, renal cell carcinoma 1118
- LAL *see* lung-associated lymph nodes
- lamina propria, intestinal epithelium 759
- Langerhans cells 73–100, 176
 - adult epidermis 77–78
 - CD68 expression 149
 - cytokeratin 82
 - dendritic cell function 82
 - epidermal 73–100
 - epidermis entry 76–79
 - homeostasis 77–78
 - immunity 75, 85–86
 - immunotherapy 88–89
 - inflammatory conditions 78
 - langerin 82
 - lectin receptors 76
 - Leishmaniasis 676
 - lineage 79–80
 - lymphoid organs 80–82
 - migration 87
 - molecular marker 73
 - morphology 75–76
 - myeloid lineage. 80
 - ontogeny 76
 - paradigm change 84–85
 - peripheral tolerance 86–88

- permissivity to HCMV 819
- tonsil 82
- transcription factor 77
- Langerhans cells differentiation 39
 - CD34⁺ hematopoietic progenitor cells 41
 - co-signals 39
 - hematopoietic progenitor cells 41
 - monocyte intermediates 40
 - progenitor cells 41
 - progenitor/stem cells 39
- Langerhans cells induction
 - precursors 41
 - TGFβ1 41
- Langerhans cells migration
 - Leishmaniasis 678
 - *Schistosoma* 717
- Langerhans-type DC, HCMV 819
- langerin
 - antibodies 89
 - CD207 73
 - Langerhans cells 82
- Lassa Virus *see* LV
- LAT, HSV-1 879
- late domain, filoviruses 831
- latency, tuberculosis 746
- latency associated proteins, HCMV 814
- latency associated transcripts
- latent infection, EBV 897
- LC 33
 - CHS 1047
- LC differentiation
 - cytokine signals 41
 - monocyte intermediates 40
 - TGF β1 39
- LC generation protocol 34
- LC induction, TGF β1-dependent 41
- LCMV 575, 839
 - cytotoxic T lymphocyte response 455
 - infection *in vivo* 386
 - Z protein 839
 - *see also* HCMV, CMV, MCMV
- LDL
 - acetylated 149
 - minimally oxidized 147
- leader peptides 361
- lectin-like oxidized LDL-receptor-1 *see* LOX-1
- lectin-like pathway, fungi 920
- lectin receptors
 - DC vaccination 1133
 - Langerhans cells 76
 - tolerance induction 571–573
- lectins
 - cancer vaccines 1097
 - C-type 407
- Leishmania*, mannose-containing carbohydrates 134
- Leishmania donovani* 582, 635, 673
- Leishmania major* 236, 361–362, 414, 487, 669, 673, 678–680
- Leishmania mexicana* 186, 190–192
 - DC 190–192
 - DC activation 191
 - promastigotes 190
- Leishmania* parasites
 - DC interaction 673–676
 - diseases 670
 - endosomal compartments 675
 - subcellular location 674–675
 - systemic administration 680
- Leishmania pifanoi* 673
- Leishmania* uptake, dendritic cell subsets 675–676
- Leishmaniasis 669–692
 - amastigote form 669
 - antigen preparation 685
 - antigenic peptide selection 686
 - chemokines 677–678
 - DALY 669
 - DC migration 676, 678
 - DC phagocytose 676
 - DC-SIGN 673
 - efficacy 686
 - HIV co-infection 669
 - IL-12 672, 681
 - immune hosts 680
 - immune induction 676
 - immune intervention strategies 685–692
 - immune response 676, 680–683
 - immunotherapy 685–686
 - inflammatory chemokine receptors 677
 - iNOS 671
 - kala-azar 670
 - Langerhans cells 676, 678
 - live parasites transportation 679
 - oriental sore 670
 - parasite persistence 680
 - parasite uptake 673–674
 - promastigote form 669
 - prophylactic vaccination 687
 - PV 674
 - recognition 681
 - regulators 669–692
 - regulatory T cells 672
 - resistance 670–673
 - susceptibility 670–673
 - T helper cells 669, 671
 - Th1/Th2 balance 672
 - Th-cell polarization 671

- therapeutic vaccination 687
- TLR 680
- travel medicine 669
- vaccination 685–686
- lentivirus, adenovirus 1149
- lethal autoimmunity, tolerance induction 576
- leucine-rich repeats 119
- leukapheresis, renal cell carcinoma 1119
- leukocyte immunoglobulin receptor *see* LIR
- leukocyte migration 296
- Lewis antigens 131, 135
- life cycle, *Schistosoma* 709
- life expectancy, transplantation tolerance 983
- lifespan 227–228
 - DC subtypes 210–211
- ligand interaction, Th-cell responses 387
- ligand receptor pairs, apoptotic cells 593
- ligands
 - HSV-1 879–880
 - prototypic long 165–168
 - TLR 120
- ligation of TLR3 436
- limitation, CTL overshoot 465–466
- lineage
 - DC subsets 53
 - hematopoietic 3
 - Langerhans cells 79–80
- lineage-restricted early hematopoietic progenitor cells 14
- lineage restriction site 54
- lipid components, *Schistosoma* 713
- lipid markers, protein transfer 506
- lipid transfer proteins *see* LTP
 - glycolipid recognition 316
- lipofection 1159–1160
- lipopolysaccharides, bacterial derived 119
- lipoproteins, tuberculosis 755
- lipoxin, *Toxoplasma gondii* 699
- LIR, pharmacologically modified DC 622
- Listeria* infection, asthma 1069–1071
- Listeria monocytogenes* 143, 363
 - expression profile of pathogens 181
 - PTX3 167
- live cells, nibbling 153, 431, 434
- live parasites transportation, Leishmaniasis 679
- liver
 - filoviruses concentration 844
 - graft rejection 971
 - malaria 654
- LN *see* lymph nodes
- LN draining lung 208
- loading of tumor antigens 1129–1142
- localization, pDCs-IPCs 227–228
- long-lived resident cells, monocytes 257–258
- long pentraxins 166
- long-term HSCs 14
- LOX-1 148
- LPC *see* lysophosphatidyl choline
- LPG, downregulation 192
- LPS, binding 412
- LRR *see* leucine-rich repeats
- LT-HSCs *see* long-term HSCs
- LTP, tuberculosis 750
- lung
 - asthma 1061–1065
 - tolerance induction 1065–1066
 - tuberculosis 749
- lung-associated lymph nodes (LAL) 745
- lupus erythematosus 303
- LV 839
 - alteration of DC function 839
 - antigen presenting function 839
 - apoptosis 839
 - enveloped virus 839
 - immature MDDCs 839
 - *Mastomys natalensis* 839
- lymph
 - DC 282
 - peripheral 282
 - steady state migration 279–294
- lymph nodes 175
 - DC migration 220
 - DC subtypes 206–208
 - DC-NK cell meeting 486–487
 - filoviruses concentration 844
 - inflamed 264
 - plasmacytoid DC 295
 - tolerogenic DC 523
- lymphatic terminology 280
- lymphocyte compartments, stimulation 899
- lymphocyte interaction 455–480
- lymphocyte responses
 - control 4–6
 - dendritic cells 4–6
- lymphocytes 4
 - homeostasis 61
 - naïve 343–345
 - NK cells 179
- lymphocytic choriomeningitis virus *see* LCMV
- lymphoid follicles, intestinal epithelium 760
- lymphoid hematopoietic progenitor cells, unexpected redundancy 16–17

- lymphoid marker, peripheral blood DC 225
 - lymphoid organs
 - DC subtypes 209–210
 - Langerhans cells 80–82
 - secondary 199–218
 - lymphoid tissue
 - enrichment of DC 203
 - extraction 203–204
 - extraction of DC 203
 - gut-associated 759–760
 - HIV infection 777
 - lymphokine-activated killer *see* LAK
 - lymphopenia, HCMV 814
 - lymphotoxin 385
 - lymphotropic wild-type viruses, measles virus 857
 - 5-lypoxygenase-dependent pathway, *Toxoplasma gondii* 700
 - lysis, NK cells 485–486
 - lyso-PS, *Schistosoma* 713
 - lysophosphatidyl choline 431
 - apoptotic cells 609
 - lysophosphatidylserine *see* lyso-PS
 - lysosomal compartments 320
 - DC vaccination 1133
 - Lysozyme-M gene 262
 - lytic infection, EBV 897
- M**
- M. africanum* 745
 - M. avium-intracellulare*-complex 747
 - M. bovis* 135, 411, 745
 - M cells
 - intestinal epithelium 759
 - *Salmonella* 733
 - M-DC8 363
 - M. kansasii* 747
 - M. leprae* 747
 - M. marinum* 747
 - M. Smegmatis* 135
 - M ϕ cells 144
 - peritoneal 149
 - receptor with a collagenous structure 144
 - treatment 145
 - Mac-1 132
 - macaque studies, HIV infection 776–777
 - macrophages 180–182, 728
 - apoptotic cells 600–601
 - clonal progenitors 14
 - EBOV 832
 - macropinocytosis 430
 - major targets, EBOV 832
 - malaria 651–668
 - acquired immunity 653–654
 - animal models 653–656
 - *Anophele* mosquito 651
 - antigen presentation 654
 - cellular immunity 654
 - complement 658
 - erythrocytic stage 654–656
 - *Grammomys surdaster* 653
 - hemozoin 657
 - immune response 654–656
 - inflammatory signals 657
 - liver stages 654
 - merozoites 652
 - monocyte differentiation 658
 - phagocytosis 658
 - *Plasmodium berghei* 653
 - *Plasmodium chabaudi adami* 653–654
 - *Plasmodium chabaudi chabaudi* 653–654
 - *Plasmodium falciparum* 651, 656
 - *Plasmodium malariae* 651
 - *Plasmodium ovale* 651
 - *Plasmodium vinckei* 653
 - *Plasmodium vivax* 651
 - *Plasmodium yoelii* 653
 - scavenger receptors 658
 - sporozoites 651
 - surface expression 660
 - T cells 654
 - *Thamnomys rutilans* 653
 - *Var* genes 652
 - Malassezia*, fungi 925
 - Malassezia furfur*, fungi 918
 - maleylated DT 151
 - malignant changes in tissues, human cancer 1083–1084
 - mammalian scavenger receptors
 - binding properties 142–150
 - structure 142–150
 - manipulate DC biology, therapeutic vaccination 1145
 - manipulating ag presentation, therapeutic vaccination 1144
 - ManLAM *see* mannosylated lipoarabinomannan
 - mannose-containing carbohydrates
 - *Candida albicans* 135
 - DC-SIGN 135
 - DC-SIGN affinity 135
 - *Helicobacter pylori* 134
 - *Leishmania* 134
 - *Mycobacteria tuberculosis* 134
 - *Schistosoma mansoni* 134
 - mannose receptors 571
 - mannosylated lipoarabinomannan
 - pathogen recognition 135

- pattern recognition 407
- MAPK *see* mitogen-activated protein kinase
- fungi 921
- Marburgvirus* (MARV) 830
- MARCO 144–146
- MARV *see Marburgvirus*
- Mastomys natalensis*, LV 839
- matrix components, recognition 167
- maturation, dendritic cells 346–347, 619–622
 - NK cells 485
 - spontaneous 355
- maturation boost, pharmacologically modified DC 619
- maturation-inducing stimuli, IL-12 family 358
- maturation inhibition, human cancer 1084–1085
- maturation resistance
 - immature DC 526–530
 - tolerogenic DC 528
- maturation signal 155
- maturation stages, migratory DC 530
- maturation status of DC, transplantation tolerance 994–997
- maturation stimuli
 - cancer vaccines 1101
 - HCMV 818
 - MCMV infection 821
- mature cell type, differentiated 14
- mature DC
 - asthma 1066–1068
 - DC-CTL interaction 464
 - HIV internalization 782
- mature DC function, HCMV 818–819
- mature DCs, pDC/IPC differentiation 233
- mature dendritic cells, migration to secondary lymphoid organs 298–301
- mature moDCs, renal cell carcinoma 1121
- matured DC, electroporation 1158
- matured moDC, HIV infection 780
- MCMV *see also* HCMV, CMV, LCMV
 - DC-NK cross-talk 490
- MCMV infection
 - apoptosis prevention 821
 - maturation stimuli 821
 - mice 820
- MCP, measles virus 857
- MDDC infection, HTV 840
- mDT *see* maleylated DT
- measles virus
 - anergy 855
 - animal model 859
 - CD40 863
 - CD46 857
 - cellular surface molecules 858
 - co-circulating genotypes 856
 - DC 859–865
 - electron micrograph 856
 - entry receptors 857–859
 - external maturation 863–864
 - functional TRAIL 864
 - genotypes 856–857
 - immunosuppressive pathogen 855
 - lymphotropic wild-type viruses 857
 - MCP 857
 - molecules on DCs interacting with MV proteins 858
 - mononegavirales 856
 - morbillivirus subgroup 856
 - MV proteins 858
 - pathogenesis 855–874
 - pleomorphic virus particle 856
 - primary infection 857
 - receptors on DC 860–862
 - SCR 857
 - secondary infections 859
 - *Sigmodon hispidus* 859
 - signaling pathways 865
 - stimulation signals 863–864
 - structure 856–857
 - surface 860–861
 - T cells 864–865
 - virus structure 856
 - wild-type strains 857
- measles virus genome 856
- mechanisms of bacterial uptake, intestinal bacteria 761
- medullary epithelial cells, tolerance induction 570
- megakaryocytes, clonal progenitors 14
- melanoma-derived exosomes 503
- membrane co-stimulators, dendritic cells 5
- membrane cofactor protein *see* MCP
- membrane fragments, protein transfer 505
- membrane proteins
 - exosomal transfer 504
 - intercellular transfer 507
 - marco 145
 - physiological role 508–509
 - transfer 504–506
- membrane receptors, reduction 299
- memory phase, immune response 238
- memory response, transfection of nucleic acids 1156
- memory T cells 235
- Mer, apoptotic cells 600
- merozoites, malaria 652

- mesenteric LN 207
- mesenteric lymph nodes *see* MLN
 - DC cunction
 - epithelial cells
 - intestinal epithelium 604
- mesenteric lymphadenectomized rats, scrapie-associated fibrils 287
- mesenteric lymphadenectomy 283
- mesenteric nodes 283
- messengers, exosomes 502
- metabolic pathway, *Candida albicans* infection 924
- metal alloys, CHS 1048
- metal-specific T cells, CHS 1050
- metastasis, activated NKT cells 325
- MFG-E8, apoptotic cells 598–599
- MHC, graft rejection 967
- MHC-associated peptides, CHS 1049
- MHC gene matching, transplantation tolerance 984
- MHC-I
 - *Salmonella* 727–728
 - tuberculosis 754
- MHC-II
 - apoptotic cells 592
 - eye 105
 - negative cell fraction 18
 - *Salmonella* 727
 - translocation 83
- MHC molecules expression, exosomes 434
- MHC-restricted presentation, systems biology 458
- mice
 - BCG-primed SR-A deficient 143
 - MCMV infection 820
 - non-obese diabetic 429
 - pDCs-IPCs 222
 - PTX3-deficient 170
- micro-environment, Th-cell responses 386
- microarrays 178
- microbes, TLR-mediated activation of DC 411–414
- microbial infections, autoimmune diseases 940, 950
- microbial instruction, dendritic cells 405–426
- microbial pathogenesis, molecular mechanisms 181
- microbial vectors 8
- microbicide strategies, HIV infection 793
- microgli 255
- microscopic cell detection, apoptotic cells 595
- migration 227–228
 - dendritic cell 279–312
 - human cancer 1085–1086
 - Langerhans cells 87
 - monocytes 267–269
 - mucosal DC 763
 - pDCs-IPCs 227
 - steady state 279–294
- migration pathways 220
 - DC 299
- migraton control, DC 295–312
- migratory activities, impairment 684
- migratory cDC 207
- migratory cells, dendritic cells 295–296
- migratory DC 175–176, 523–524
 - apoptotic cells 603
 - steady-state 530
- migratory fate, lymph dendritic cells 285–286
- milk-fat globule protein, apoptotic cells 598–599
- mimicry, apoptotic cells 607–608
- mitogen-activated protein kinase cascade pathway 29
- mixed chimerism
 - immune intervention 1005
 - transplantation tolerance 999
- mixed lymphocyte reaction, allogeneic 221
- mLDL *see* modified low density lipoprotein
- MLN
 - intestinal epithelium 760
 - *Salmonella* 724
- MLNX *see* mesenteric lymphadenectomy
- MLR *see* mixed lymphocyte reaction
- MMF, T cells regulation 1000
- moDC *see* monocyte-derived DC
 - modification by viral factors 790
- model allergen ovalbumin, asthma *see* OVA
- modified low density lipoprotein 141
- modularity, DC-CTL interaction 457–458
- modulated DC populations, tolerance-associated genes 629–632
- modulation
 - antigen presentation 728–729
 - cell activation 155
 - DC functions 416, 866
 - DC populations 629–632
 - DC-NK cross-talk 489–490
 - dendritic cell activation 155
 - dendritic cell phenotype 155
 - immune responses 129–140, 325–327
 - tissue factors 395
 - TLR expression 392–393
- MOG 574

- molecular determinants, monocyte differentiation 260–261
- molecular marker, Langerhans cells 73
- molecular mechanisms
 - apoptotic cells interaction with DC 602–605
 - NK cells activation 483–484
- molecular ‘ping-pong’ interactions, DC-CTL interaction 464–465
- molecular profile, DC activation 190–192
- molecules, prototypic long 165–168
- molecules on DCs interacting with MV proteins, measles virus 858
- Monkey, pDCs-IPCs 222
- monoclonal antibodies 363
 - specific for IPCs 222
- monocyte-derived DC 31, 777
 - generation 42
 - plasticity 1099
- monocyte differentiation 256
 - malaria 658
 - molecular determinants 260–261
- monocyte intermediates, LC differentiation 40
- monocyte subsets 253–278
- monocytes 266, 814
 - activation 229
 - additional subsets 266–267
 - autoimmune diseases 941
 - cytokines 42
 - DC 42, 253–278
 - differentiation 260–261
 - EBOV 832
 - HCMV 814–815
 - heterogeneity 261
 - individual subsets of the mps system 260
 - infection 259–260, 268–269
 - inflammation 259–260, 268–269
 - intermediates 40
 - LC differentiation 40
 - long-lived resident cells 257–258
 - migration 267–269
 - molecular determinants 260–261
 - peripheral tissues 257–258, 268
 - plasticity 256, 1099
 - recruitment 268–269
 - short-lived bone marrow-derived resident cells 258–259
 - short-lived cells 259–260
 - target tissues 267–268
- mononegavirales, measles virus 856
- mononuclear phagocyte system 254
 - blood monocytes 254–256
 - mononuclear phagocytes, PTX3 production 168
 - morbillivirus subgroup, measles virus 856
 - morphological transition, fungi 915
 - mosquitoes, DEN 835
 - mouse bone marrow, pDC conversion 226
 - mouse DC subsets, phenotype 226
 - mouse dendritic cell populations, Th-cell responses 388
 - mouse macrofialin 149–150
 - mouse model, HCMV 820–821
 - Mouse pDCs/IPCs, isolation 222
 - mouse tumor models, ex vivo tumor vaccination 1151–1153
 - MPP *see* multipotent progenitors
 - MPS *see* mononuclear phagocyte system
 - MPS system, individual subsets 260
 - mRNA
 - electroporation 1157
 - hierarchical clustering 191
 - mRNA processing, HSV-1 886–887
 - mRNA receptor expression, downregulation 299
 - MSC, DC precursors 524
 - MUC1, human cancer 1083, 1086
 - mucosal DC
 - gut-homing T cells imprint 763
 - HIV infection 776–777
 - migration 763
 - unique functions 763–764
 - mucosal epithelial cells 180–182
 - mucosal immune responses, intestinal epithelium 760
 - mucosal infection, blocking 793
 - mucosal surfaces, HIV infection 774
 - mucosal tissues, HIV infection 777
 - mucous glycocalyx, intestinal epithelium 759
 - multimerization, receptor 130
 - multiple Ag loading, adenovirus
 - multiple sclerosis
 - defective abnormalities in DC 947
 - tumor necrosis factor-alpha 31
 - multiple tumor antigens sources, DC vaccination 1133
 - multipotent progenitors 14
 - multivesicular bodies *see* MVB
 - murine cytomegalovirus infection *see* MCMV
 - murine DC, *Toxoplasma gondii* 696–698
 - murine DC phagocytose, fungal morphotypes 919
 - murine infection models 733–737
 - murine spleen DC, subsets 122

- murine suppressive DC precursors 525
 - mutations, *Salmonella* 732
 - MV *see* measles virus
 - MV-DC interaction, functional consequences 860–862
 - MV proteins, measles virus 858
 - MVB, exosomes 499
 - Mycobacteria* 414, 416
 - DC function diversion 755
 - tuberculosis 747–748
 - Mycobacteria*-infected macrophages, tuberculosis 752
 - mycobacterial lipoproteins, tuberculosis 755
 - mycobacterial PAMP 746
 - Mycobacterium avium*, Th2-cell development 395
 - Mycobacterium leprae*, langerin 85
 - Mycobacterium tuberculosis* 408, 483, 713, 745
 - cytokines production 357
 - mannose-containing carbohydrates 134
 - mannosylated lipoarabinomannan 135
 - Th-cell responses 390
 - mycophenolate mofetil *see* MMF
 - Mycoplasma fermentans* 361
 - mycoplasmal diacyllipopeptides 411
 - MyD88 *see* myeloid differentiation, 123, 231
 - crosspresentation 435
 - tuberculosis 754
 - myeloid cells, pattern recognition receptors 141
 - myeloid DC 165–174, 233, 406
 - blood-circulating 169–170
 - conventional 237–238
 - cytokines 33, 35
 - expansion 36–38
 - pre-expansion 35
 - progenitors 4
 - promotion 36–38
 - PTX3 source 168–169
 - recruitment 296–298
 - subsets 33
 - TLR ligation 407
 - type 1 IFN 233
 - myeloid differentiation, HCMV 815
 - myeloid genes, PU1 56
 - myeloid lineage
 - HCMV 814–815
 - HCMV reservoir 815
 - Langerhans cells 80
 - myeloid marker, peripheral blood DC 225
 - myeloid restricted hematopoietic progenitor cells, unexpected redundancy 16–17
 - myeloid suppressor cells *see* MSC
 - myelomonocyte surface antigens, human pDC 36
 - myriocin 304
 - mysterious cell type, type 1 IFN σ 221
- N**
- N terminus, virus replication 783
 - NADPH oxidase, *Salmonella* 725–726
 - naïve helper T cells 385
 - naïve T cells 235
 - naïve T lymphocytes, activation 343–345
 - natural cytotoxicity receptors *see* NCR
 - natural defense, mediation by stromal cells 405
 - natural interferon-producing cells
 - bone marrow progenitors 13
 - Flt3-license 18–20
 - precursors 17
 - proposed models 15–16
 - unexpected redundancy 16–17
 - natural killer cells 255, 481–498
 - natural regulators, pharmacologically modified DC 619
 - NCR, EBV 898
 - necrosis 155
 - necrotic cell death, graft rejection 971
 - necrotic cells 432
 - human cancer 1083
 - human mDCs 429
 - receptors involved in recognition 431
 - uptake 155
 - Nef gene, HIV infection 783
 - negative control, immune system 619
 - negative selection, autoimmune diseases 937
 - negative signal induction, tolerance induction 577–579
 - Neisseria meningitidis* 143, 145, 156, 408
 - nematode glycoprotein ES-62, Th-cell responses 390
 - neonatal Fc receptors *see* Fc receptors
 - nephrectomy, renal cell carcinoma 1122–1123
 - network, transcription factors 53–71
 - neutralizing anti-envelope antibodies, HIV infection 789
 - neutrophils 132, 180–182
 - *Salmonella* 737
 - new world HTV 840
 - NF- κ B, DC maturation 55
 - NF-AT activation, T cell tolerance 519
 - Ni $^{2+}$ ions, CHS 1049
 - nibbling from live cells 434

nickel-binding proteins, CHS 1051–1053
 nickel contact dermatitis, CHS 1048
 nickel epitopes presentation, CHS 1049–1050
 nickel ions, TCR-MHC crosslinkers 1050–1051
 nickel presentation 1047–1058
 – CHS 1051
 – human T cells 1048–1051
 nickel transport, CHS 1052
 nitrogen intermediates, *Salmonella* 726
 NK cell activity, HCMV 820
 NK cells 481–482
 – activation 482–484
 – ADCC 483
 – CD lysis 485–486
 – CD94/NKG2A inhibitory receptor 485
 – cytolytic activity 179
 – cytotoxicity 484
 – DC maturation 485
 – DC subsets 483–484
 – DC-NK cross-talk 492
 – immunosurveillance 481
 – inflammation 486
 – inhibitory receptor 485
 – lymphocytes 179
 – lysis 485–486
 – maturation 485
 – molecular mechanism 483–484
 – non-MHC-restricted cells 482
 – pDCs/IPCs 238
 – priming 180
 – reciprocal interaction 484–486
 – regulation 238, 898
 – subset 485
 – transplant tolerance 1034
 NK-DC interplay 179–180
 NKT cell responses, functional diversity 323–325
 NKT cells 313–342
 – adjuvant-like effect 327
 – antigen presentation 319–321
 – APC 322
 – CD1d-restricted 328
 – cross-talk 322
 – cytolytic effector mechanisms 322
 – cytotoxicity 322
 – definition 318–319
 – effector functions 321–327
 – functional diversity 323–325
 – immunoregulatory role 328
 – pro-inflammatory factors 322
 – self-reactivity 324
 – semi-invariant TCR 313

– subsets 319
 NOD-like proteins 141
 NOD proteins, epithelial cells 762
 non-HLA restricted nickel presentation, CHS 1051
 non-MHC-restricted cells, NK cells 482
 non-obese diabetic mice 429
 nonchemokine chemotactic receptors 301
 nonchemotactic signals, tuning dendritic cell migration 303–305
 nonlymphoid organs, sentinel DC 73–198
 nonspecific esterase 286
 notch factors 54
 notch ligands, tolerance induction 579–580
 novel genes, identification 634–636
 novel immune intervention strategies, Leishmaniasis 685–688
 NSE *see* nonspecific esterase
 nuclear antigen 1 of EBV *see* EBNA1
 nucleic acid transfer 1143–1172
 nucleocapsids, HSV-1 878

O

ocular immune privilege 101
 old world HTV 840
 oligonucleotide microarrays 178
 ongoing asthmatic inflammation 1066–1068
 onset, HIV infection 774–776
 ontogeny, Langerhans cells 76
 open reading frames, ebolavirus 831
 opposing concepts, Th-cell responses 388–392
 opsonins, fungi 923–924
 opsonized pathogens uptake, DC vaccination 1131–1132
 opsono-dependent pathways, fungi 920
 oral hairy leukoplakia, EBV 898
 oral *Salmonella* infection 736
 organ confined renal cell carcinoma 1122–1123
 organ ischemia, graft rejection 971
 organ transplantation 967–971, 1026
 organs, nonlymphoid 73
 oriental sore, Leishmaniasis 670
 osteoporosis, tumor necrosis factor-alpha 31
 OT-I mice 88
 OVA
 – asthma 1065
 – maleylation 152
 ovarian epithelial cell carcinomas 240
 OX40L
 – asthma 1069

- murine 415
 - *Schistosoma* 716
 - Th2 induction 235
 - oxidative cellular stress, graft rejection 971
 - oxidative stress, apoptotic cells 595
- P**
- paired immunoglobulin-like receptor
 - see* PIR
 - PAMP *see* pathogen-associated molecular patterns
 - fungi 916
 - *Schistosoma* 709
 - toll-like receptors 120
 - tuberculosis 750
 - Paracoccidioides brasiliensis*, bound by PTX3 167
 - parasitemia 661
 - DC function 662
 - parasites 651–722
 - DC function 683–684
 - Leishmaniasis 673–674, 680
 - *Toxoplasma gondii* 696–698
 - parasitophorous vacuoles *see* PV
 - *Toxoplasma gondii* 702
 - Parkinson's disease, CRT 984
 - partial nephrectomy, renal cell carcinoma 1122–1123
 - passenger leukocyte, transplantation tolerance 985
 - passive pulsing, transfection of nucleic acids 1155–1156
 - pathogen-associated molecular patterns
 - see* PAMP, 181, 406
 - pathogen elimination, bacteria 723
 - pathogen interaction, dendritic cells 182–183
 - pathogen receptors, CLR 133
 - pathogen recognition
 - DCs 134–136
 - Th-cell responses 392
 - tolerogenic DC 517
 - pathogenesis
 - HTV 840
 - measles virus 855–874
 - transmissible spongiform encephalopathies (tse) 287–288
 - pathogenic autoimmunity 940
 - pathogenicity, intestinal bacteria 760
 - pathogens 185
 - apoptotic cells 607–608
 - bound by PTX3 167
 - CLR 133
 - DC-SIGN 841
 - dendritic cells 182–183
 - Hepatitis virus 125
 - inhibitory mechanisms 125
 - measles virus 855–874
 - profiling 180–182
 - transmissible spongiform encephalopathies 287–288
 - *Vaccinia* virus 125
 - pathology
 - CMV infection 814
 - DEN 835
 - filoviruses 830–831
 - pathways, allorecognition 968, 1020
 - crosspresentation 5
 - DC activation 298
 - DC development 27
 - graft rejection 967–970
 - pDC/IPC differentiation 233
 - T cell activation 345
 - *Toxoplasma gondii* 698
 - transplantation tolerance 987
 - patient selection, renal cell carcinoma 1123
 - pattern recognition receptors 119, 129, 141
 - apoptotic cells 593
 - autoimmune diseases 943
 - cancer 1134
 - DC activation 468–469
 - dendritic cells 406
 - epithelial cells 762
 - Epstein-Barr virus 904
 - fungi 916
 - immune recognition 656
 - lung dendritic cells 1063
 - monocyte subsets 256
 - mucosal epithelial cells 181
 - pDC precursors 228
 - peripheral blood DC 225
 - phagocytic synapse 593
 - *Toxoplasma gondii* 694
 - Tuberculosis 746
 - Pax5 60
 - PD-1 *see* programmed cell death
 - pDC 219–252
 - asthma 1066
 - differentiation 234
 - generation 37
 - graft-versus-host disease 976
 - haart treatment 791
 - HIV infection 777
 - TLR expression profiles 406
 - pDCs/IPCs 227–229
 - B-cell function 239
 - chemokine receptors 227
 - cross-priming 236

- development 224–227
- differentiation 233
- dominant-negative transcription factors 224
- functional plasticity 234
- Giesma staining 223
- human diseases 231–233, 239
- IFN- α 230–231
- IFN-producing cells 229–230
- immune responses 228–238
- intracellular TLR-7 228–229
- isolation 222
- isolation and characterization 222–224
- localization 227–228
- mature DCs 233
- mice 222
- migration behavior 227
- Monkey 222
- morphology 223
- NK cell function 238
- pathways 233
- Pig 222
- Rat 222
- regulatory T cells 236
- selective expression 229
- surface phenotype 224
- type 1 IFN-producing cells 229–230
- viral infection 237
- pDNA, electroporation 1156
- penetration, *Salmonella* 733–734
- pentraxin 598
 - production 165–174
- pentraxin 3 *see* PTX3
- peptide-chaperone complexes, crosspresentation 153–155
- peptide complexes uptake, DC vaccination 1132
- peptide epitopes, muc1 1084
- peptide-MHC complexes, signal 1 343
- peptide-pulsed DCs, cancer vaccines 1102
- peptides
 - CHS 1047
 - presentation 592
 - transfer 441
- peri-transplant treatment, transplant tolerance 1026
- perinuclear ER compartment, access 439
- peripheral blood DC
 - differentially expressed antigens 225
 - human 225
 - lymphoid marker 225
 - myeloid marker 225
 - pattern recognition receptors 225
- peripheral lymph 280
 - dendritic cells entry 282
- peripheral organs, migratory DC 523–524
- peripheral regulation, alloreactive T cells 1000–1001
- peripheral tissues
 - constitutive migration 281–282
 - dendritic cells exit 282
 - monocytes 257–258
 - monocytes recruitment 268
- peripheral tolerance 570–571, 575–577
 - apoptotic cells 605–607
 - autoimmune diseases 938
 - DC and apoptotic cells 603–605
 - eye 104
 - Langerhans cells 86–88
 - resting DC 573
 - autoimmune diseases 946–947
 - peripherally induced, T cells
 - periphery, DC-NK cell meeting 487
 - peritoneum, inflamed 264
 - permissivity to HCMV, Langerhans-type DC 819
- peroxisome-proliferator-activated receptor γ
 - see* PPAR- γ
- Peyer's patches
 - fungi 923
 - intestinal epithelium 759
- PGD₂, *Schistosoma* 717
- phago-lysosomes formation 436
- phagocytes 430, 600
 - apoptotic cells 594
 - mononuclear 254–256
 - *Salmonella* presence 733
- phagocytic activity
 - hierarchic 675
 - spleen subtypes 209
- phagocytic cells 180–182
- phagocytic synapse, apoptotic cells 593
- phagocytose, apoptotic cells 592
- phagocytosed antigens, DC vaccination 1134
- phagocytosis
 - bacteria 723
 - crosspresentation 438
 - malaria 658
- phagosomal environments, *Salmonella* survival 728
- phagosome-endosome compartment 438–439
- phagosome maturation, regulation 436
- phagosomes, DC vaccination 1134
- pharmacological agents, T cells regulation 1000

- pharmacological manipulation, tolerance induction 1027–1028
- pharmacologically modified DC 619–648
 - adaptive regulators 619
 - AE 624
 - crosspresentation 622
 - DEC-205 621
 - gene profiling 622
 - ILT 622
 - incomplete signals 621
 - LIR 622
 - maturation boost 619
 - natural regulators 619
 - PIR 622
 - SAGE 624
- pharmacologically-treated DC, transplantation tolerance 1001
- phenotypes
 - DC-CTL interaction 464
 - Flt3 ligand 29
 - malaria 658
- phoP/phoQ regulatory system, *Salmonella* 728
- phosphatidylinositol 3-kinase pathways 29
- phosphatidylserine *see* PS
- phosphoinositide-3 kinase, migration 299
- phosphorylation, fl binding 29
- physiological role
 - exosomes 502–504
 - membrane protein swapping 508–509
- physiopathology, DC-NK cross-talk 490
- PI3-K *see* phosphatidylinositol 3-kinase pathways
- PI3Ky *see* phosphoinositide-3 kinase
- Pig, pDCs-IPCs 222
- ping-pong interactions, DC-CTL interaction 464–465
- PIR, pharmacologically modified DC 622
- plasma cell differentiation, SLE 948
- plasmacytoid DC 13, 27, 120, 169–170, 203–204, 406
 - DC development 36–38
 - differentiation pathway 466
 - high endothelial venules 297
 - inhibition 36–38
 - lymph node entry 295
 - precursors 219–252
 - recruitment 296–298
 - SLE 947–948
 - suspension cultures 36–38
 - T cell responses 349
 - tolerogenic DC 524
 - transplantation tolerance 991
- plasmacytoid morphology 219–221
- plasmid DNA *see* pDNA
- Plasmodium*, exogenous ligands 320
- Plasmodium aeruginosa*, PTX3 169
- Plasmodium berghei*, malaria 653
- Plasmodium chabaudi adami*, malaria 653–654
- Plasmodium chabaudi chabaudi* 653–654, 659
- Plasmodium falciparum* 147, 408, 415
 - malaria 651, 656
- Plasmodium malariae*, malaria 651
- Plasmodium ovale*, malaria 651
- Plasmodium vinckei*, malaria 653
- Plasmodium vivax*, malaria 651
- Plasmodium yoelii* 653, 659
- plasticity
 - dendritic cells populations 385–404
 - monocyte-derived DC 1099
 - monocytes 256
 - T cell response 916
- pleiotropic cytokine 360
- pleomorphic virus particle, measles virus 856
- polarization, T helper cells 682–683
- polarization of CD4⁺ T cell responses, EBNA1 901–902
- polarized T helper responses, Leishmaniasis 669
- polarizing cytokines, signal 3 343
- polarizing molecules, T cells 407
- polyadenylation signal 628
- polyclonal antibody, human marco 146
- polymorphonuclear cells 255
- populations, dendritic cells 385–404
- portal for pathogens, DC-SIGN 841
- post-translationally modified proteins, human cancer 1083
- potential cellular targets, HIV infection 774
- potential target cells, HCMV 815–816
- PPAR- γ , intestinal bacteria 763
- PPR *see* pattern recognition receptors
- pre-expansion, myeloid DC progenitor cells 35
- pre-programmed Th-cell development 388–392
- precursors
 - circulating dendritic cells 219–278
 - IL-1 synthesis 361
 - intermediate 16
 - LC induction 41
 - plasmacytoid dendritic cell 219–252
- presentation
 - acquired immune system 151

- DC subsets 428
- endogenous antigens 235
- exogenous antigens 235
- glycolipid 315
- immune system 151
- *L. major* antigen 678–680
- peptides 592
- *Salmonella* 727–728
- *Salmonella* antigens *in vivo* 736–737
- preventative HIV vaccines 795–796
- preventing direct HIV interactions 788
- prevention, HSV-1 specific immune responses 877
- primary CTL responses, transfection of nucleic acids 1156
- primary immune responses, asthma 1062–1065
- primary infection, measles virus 857
- primary inflammatory signals, PTX3 168
- primary responses, HIV vaccines 795–796
- priming
 - autoimmune diseases 939–945
 - indirect 416
 - inflammatory T cell responses 348
 - T cell responses 348
 - Th cell responses 348
- primitive macrophages 257
- prion-related protein 287
- pro-inflammatory, transcriptional response 190
- pro-inflammatory cytokines 360, 362
 - cancer vaccines 1101
 - DC activation 182
 - tuberculosis 753
- pro-inflammatory factors, NKT cells 322
- process apoptotic cells 592
- professional migratory cells, dendritic cells 295–296
- professional type 1 interferon-producing cells 219–252
- profiling, pathogens 180–182
- progenitor cells
 - development 16–17
 - hematopoietic 18–20, 33
 - LC differentiation 41
 - lineage-restricted 14
 - pre-expansion 35
- progenitors
 - DC 13
 - myeloid 4
 - stem cells 39
- progeny virions assembly, DEN 836
- programmed cell death 411
 - interaction with DC 591
- programmed differentiation, CTL 462
- proinflammatory cytokine response, EBV 903
- proliferation
 - antigen-specific T cells 573
 - EBOV 833
 - T cells 386
- promastigotes
 - *Leishmania mexicana* 190
 - Leishmaniasis 669
- promoting factors, regulatory T cells 410–411
- prophylactic vaccination, Leishmaniasis 687
- Prophyomonas gingivalis* 412
- protease sensitive, *Toxoplasma gondii* 697
- proteasome, DC vaccination 1134
- protective IgG, parasite growth 655
- protective immunity, fungi 916
- protective immunity to inhaled antigens, asthma 1063
- protectiveness, semi-mature DC 529
- protein destruction, exosomes 502
- protein swapping 508–509
- protein transfer 499–516
 - cell-cell contact 506
 - contact-dependent 504–506
- proteins
 - filoviruses 834–835
 - tumor cells 1083
- proteolysis, antigens 437
- protocols, DC-CTL interaction 457–458
- prototypic long PTX3 molecules 165–168
- protozoan, *Toxoplasma gondii* 693
- PrP *see* prion-related protein
- PRR *see* pattern recognition receptors
- PS, externalized 595
- pseudo-afferent lymph 282–283
- Pseudomonas aeruginosa* 14
 - bound by PTX3 167
 - expression profile of pathogens 181
- psoriasis vulgaris, IL-23, *in-situ* expression 359
- PTX3
 - antigen presenting cells 170
 - APC 170
 - apoptotic cells 598
 - *Aspergillus fumigatus* 169–170
 - blood-circulating myeloid 169–170
 - *Burkholderia cepacia* 167
 - *Candida albicans* 167
 - *Escherichia coli* 167
 - female fertility 166
 - innate immunity 170–171

- *Listeria monocytogenes* 167
- mice 170
- mononuclear phagocytes 168
- myeloid DC 168–169
- primary inflammatory signals 168
- production 165–174
- *Pseudomonas aeruginosa* 169
- TLR family 168
- PU.1 56
- potential antagonist 60
- transactivation repression 57
- pulmonary syndrome, HTV 840
- PV, Leishmaniasis 674

- Q**
- quality of life, renal cell carcinoma 1123–1124
- quiescent monocytes, autoimmune diseases 941

- R**
- R-Nef isoform, virus replication 783
- R5 HIV isolates, HIV infection 793
- RA, defective abnormalities in DC 947
- radical nephrectomy, renal cell carcinoma 1122–1123
- rapid perturbation, systems biology 458
- rapid signal amplification, DC-CTL interaction 464–465
- rapid turnover, steady state spleen cDC 210
- rat
 - lymph dendritic cells 283–286
 - mesenteric lymphadenectomized 287
 - pDCs-IPCs 222
- RBC, malaria infected 652
- RCC 1117
- rDC *see* resident dendritic cells
- reactive oxygen, *Salmonella* 726
- receptors
 - antigen uptake 5
 - apoptotic cells 431
 - *Aspergillus fumigatus* 922
 - *Candida albicans* 922
 - crosspresentation sources 430
 - cytokine 18
 - DC vaccination 1130–1131
 - exosomes 431
 - flagellin 119
 - Flt3 18, 28
 - fungi 918–918, 922
 - GM-SCF 29
 - heat shock proteins 431
 - HIV infection 778–780
 - HSV-1 879–880
 - IL-12R 408
 - IL-23 408
 - immune complexes 431
 - inflammatory chemokines 296
 - interleukin 4 30
 - interleukin 15 31
 - interleukin 3 30
 - measles virus 860–862
 - multimerization 130
 - necrotic cells 431
 - pattern recognition 406
 - T cell activation 345
 - tolerance induction 572–573, 577–579
 - transforming growth factor beta-1 32
 - tumor necrosis factor-alpha 31
 - tyrosine kinase subclass III family 28
- recipient conditioning, graft-versus-host disease 975–976
- recipient DC, tolerance induction 1032
- reciprocal interaction, NK cells 484–486
- recognition
 - alloantigen 967–970
 - apoptotic cells 599–600
 - bacteria 148
 - DC subtypes 201–202
 - double-stranded DNA 228–229
 - glycosylated self-antigens 131
 - Leishmaniasis 681
 - matrix components 167
 - single-stranded RNA 228–229
 - tumor cells 427
- recombinant adenovirus, therapeutic vaccination 1146–1149
- reconstitution, graft-versus-host disease 976–977
- recruitment, monocytes 268–269
- recruitment
 - blood monocytes 262
 - DC-CTL interaction 464
 - mDC 296–298
 - pDC 296–298
 - tissues 267–269
- red blood cells *see* RBC
- redundancy, systems biology 460–461
- redundant activating signals, DC-CTL interaction 466–468
- redundant receptors, apoptotic cells 600
- reg T *see* regulatory T cells
- regulation
 - B cells function 239
 - B-cell function 239
 - conventional myeloid DC 237–238
 - DC activity 699
 - DC vaccination 1135

- immune cells 238
 - immune responses 233–238, 680–683
 - *in vitro* DC hematopoiesis 33–43
 - *Leishmania*-specific immune response 680–683
 - NK cell function 238
 - phagosome maturation 436
 - T cell tolerance 521
 - regulators, Leishmaniasis 669–692
 - regulatory cells, tuberculosis 752–753
 - regulatory DC, transplantation tolerance 993
 - regulatory effects 600–602
 - regulatory mechanisms, cancer vaccines 1104–1106
 - regulatory T cell-promoting DC 415
 - regulatory T cell responses, DC-derived factors 408–411
 - regulatory T cells 236, 405, 410
 - activated 489
 - adaptive 406
 - DC-NK cross-talk 489–490
 - fungi 926–927
 - induction 579–580
 - Leishmaniasis 672
 - pDCs-IPCs 236
 - subsets 406
 - T cell tolerance 521, 1023–1025
 - tolerance induction 578–579
 - regulatory-tolerogenic DC 582
 - rejection process, prophylactic intervention 988
 - rejection response 1017–1019
 - relative gene expression patterns, DC populations 631
 - RelB 55–56
 - renal cell carcinoma *see* RCC, 1117–1128
 - adjuvant immunotherapy 1122–1123
 - adverse effects 1123–1124
 - antigens 1122
 - cancer immunosurveillance 1117–1118
 - CD14⁺ cells 1119
 - clinical 1119–1122
 - DC-based immunotherapy 1119–1122
 - GM-CSF 1118
 - immunogenicity 1121
 - immunosurveillance 1117–1118
 - immunotherapy 1118–1123
 - kidney tumor 1118
 - LAK 1118
 - leukapheresis 1119
 - mature moDCs 1121
 - nephrectomy 1122–1123
 - patient selection 1123
 - quality of life 1123–1124
 - survival time 1118
 - TIL 1118
 - tumor-associated antigens 1121
 - two-step culture system 1119–1120
 - xeno-antigen 1121
 - renal syndrome, HTV 840
 - reperfusion injury, graft rejection 971–972
 - replication
 - DEN 836
 - filoviruses 831
 - HCMV 816–817
 - HSV-1 878–879
 - replication cycle, HSV-1 876
 - resident cells
 - bone marrow-derived 258–259
 - long-lived 257–258
 - resident dendritic cells 176
 - resistance
 - HIV infection 780
 - immature DC 526–530
 - Leishmaniasis 670–673
 - response, development 385
 - response quality, cancer vaccines 1102
 - response- skewing cytokines, bacteria 723
 - resting DC
 - peripheral tolerance 573
 - tolerance induction 574–575, 577–579
 - resting immune cells, protein transfer 505
 - retina, DCAPC 103–104
 - retrovirus, adenovirus 1149
 - rheumatoid arthritis
 - dendritic cell manipulation 546
 - inflammatory sites 945
 - pDCs/IPCs 227
 - tumor necrosis factor-alpha 31
 - RMA-S-Rae1 β , tumor model 488
 - RNA-positive LCs, HIV infection 776
 - RNA viruses 829
 - robust biological system, DC-CTL interaction 456
 - rodent malaria, DC 659–660
 - RTK 28
 - Runx3 64
- S**
- Saccharomyces cerevisiae*, fungi 918
 - SAF *see* scrapie-associated fibrils
 - SAGE
 - experimental procedure 626
 - library comparisons 634–636
 - pharmacologically modified DC 624
 - tags 632
 - Salmonella* 414, 438

- adaptive immunity 734–737
- antigen presentation 727
- bacterial uptake 724–727
- cell death 730
- co-stimulation 735
- cytoskeleton rearrangement 725
- DC maturation 723, 730–732, 734–736
- DC subsets 724–730
- expression profile of pathogens 181
- GFP-expressing bacteria 731
- immunity 723
- infected DC 727
- inhibitory cytokines 731
- iNOS 725
- internalized bacteria 724–727
- intestinal epithelium 733–734
- M cells 733
- MHC 727–728
- MHC-I 727–728
- MHC-II 727
- MLN 724
- mutations 732
- NADPH oxidase 725–726
- neutrophils 737
- nitrogen intermediates 726
- penetration 733–734
- phagocytes 733
- phagosomal environments 728
- phoP/phoQ regulatory system 728
- reactive oxygen 726
- SCV 725
- Serovar Typhimurium 724
- TAP 727
- wild type 727
- Salmonella* antigen presentation, *Salmonella* 727
- Salmonella enterica* Serovar Typhimurium 724
- Salmonella* infection 733–736
- Salmonella typhimurium* 413, 763
 - apoptotic cells 609
 - bound by PTX3 167
 - infection 765
- SAP, apoptotic cells 598
- saposin, tuberculosis 750
- scavenger receptors
 - Ag 152–153
 - cell biology 150–156
 - class A 143–147
 - cross-talk 156
 - cysteine-rich domain 143
 - dendritic cell activation 155
 - dendritic cell biology 150–156
 - dendritic cells 141–164
 - family 142, 147, 149–150
 - function on DC 150
 - *in vitro* generation 151–152
 - internalization 151
 - malaria 658
 - mammalian 142–150
 - SR-A 143–144
 - types 143–147, 149–150
- SCF *see* stem cells
- Schistosoma* 709–722
 - antigen 710–717
 - B cells 716
 - carbohydrate components 713
 - cercarial-derived prostaglandins 717
 - C-type lectins 713
 - DC function 136
 - DC response 710–717
 - DC-SIGN 713
 - human monocyte-derived DC 713
 - IL-10 713, 715
 - immunity 711
 - inflammatory TLR ligands 714
 - Langerhans cells migration 717
 - life cycle 709
 - lipid components 713
 - lyso-PS 713
 - OX40L 716
 - PAMP 709
 - PGD₂ 717
 - schistosome Ag 714–717
 - T cell response 711
 - Th1/Th2 effector function bias 709
 - Th2 induction 714–717
 - TLR-initiated signaling 712
 - tolerogenic DC 714
- Schistosoma* egg antigen 391, 395
- Schistosoma haematobium* 709
- Schistosoma japonicum* 709
- Schistosoma mansoni* 135–136, 305, 412, 416, 709
 - mannose-containing carbohydrates 134
 - specific signature 186–189
- Schistosoma mekongi* 709
- Schistosoma typhimurium* 733
- schistosome infection 717
- schistosomula 710
- schizont stage, malaria 652
- SCR, measles virus 857
- scrapie-associated fibrils 287
- SCV, *Salmonella* 725
- SEA *see* *Staphylococcus enterotoxin A*, 710
- SEA-specific Th2 responses 714
- Sec61, crosspresentation 439
- secondary immune challenge, asthma 1066

- secondary infections, measles virus 859
 secondary lymphoid organs 286
 – dendritic cells 199–218
 secretion
 – exosomes 499–500
 – filoviruses 833
 selective responsiveness, cytokines
 production 363
 self antigen presentation, autoimmune
 diseases 938, 946
 self antigen specific T cells, autoimmune
 diseases 937
 self antigens
 – DC 523
 – migratory DC 530
 – tolerance 427, 469–470
 self antigens transport, apoptotic cells 604
 self-chromatin-antichromatin antibody
 complexes 237
 self-glycolipids 320
 self-ligands 320
 self-proteins, apoptotic cells 591
 self-reactive T cells, tolerance induction
 1021
 self-reactivity, NKT cells 324
 self-tolerance, transplantation tolerance
 989–997
 semi-direct alloantigen presentation pathway
 – graft rejection 969–970
 – transplantation tolerance 987
 semi-direct pathway of presentation,
 tolerance induction 1002
 semi-invariant TCR, NKT cells 313
 semi-mature, dendritic cells 284–285
 semi-mature cells, transplantation tolerance
 997
 semi-mature DC 528
 semi-mature TNF/DC, properties 529
 Semiliki Forest Virus 436
 sensitization
 – asthma 1062–1065
 – transplantation tolerance 986
 sensitization phase, CHS 1047
 sensors of infection, dendritic cells 183–185
 sentinel DC, nonlymphoid organs 73–198
 sentinels, dendritic cells 175
 septic shock, sage library comparisons 635
 sequestration, malaria 652
 serial analysis of gene expression
 see SAGE
 serotypes, DEN 844
 Serovar Typhimurium, *Salmonella* 724
 serum amyloid P *see* SAP
 SFV *see* Semiliki Forest Virus
 short consensus repeats *see* SCR
 short-lived bone marrow-derived resident
 cells 258–259
 short-lived cells, monocytes contribution
 259–260
 short pentraxins 166
 short-term HSCs 14
 SifA-expressing *Salmonella* 727
Sigmodon hispidus, measles virus 859
 signal 1 343
 signal 2 343
 signal 3 343
 signal amplification, DC-CTL interaction
 464–465
 signal induction, tolerance induction
 577–579
 signal pathway, TLR 123
 signal strength, DC-CTL interaction 462
 signal transducer and activator of
 transcription 29
 signal transduction
 – Flt3 ligand 29
 – GM-SCF 29
 – interleukins 30–31
 – tumor necrosis factor-alpha 32
 signal transduction events, fungi 921
 signaling pathways 54
 – fungi 918
 – graft-versus-host disease 976
 – *Toxoplasma gondii* 696
 – measles virus 865
 – virus replication 783
 signaling process, naïve T lymphocytes 343
 signaling receptors, CLR 136
 signals
 – balance 577
 – DC-CTL interaction 466–468
 – nonchemotactic 303–305
 signatures, tolerance-associated genes
 632–634
 silencing constructs, ES cells 1006
 simian immunodeficiency virus *see* SIV
 macaque system
 simultaneous assessment, tolerance
 associated 636–637
 simultaneous triggering, TLR 348
sin nombre, HTV 840
 single-stranded RNA, recognition 228–229
 siRNA, DC-SIGN 841
 sites of alloantigen presentation, graft
 rejection 970–971
 SIV macaque system, HIV infection 776
 Sjögren's syndrome, defective abnormalities
 in DC 947

- skin graft rejection 970
- skin-sensitizers, CHS 1047
- skin-test-positive donors, tuberculosis 750
- SLE *see* systemic lupus erythematosus
- soluble antigens
 - intestinal epithelium 760
 - mechanism 439–440
- soluble extracellular domain, CD83 887–888
- soluble receptor-related subunit 357
- sorting events 134
- SoS *see* stimulation
- spatiotemporal view, DC-CTL interaction 469
- special DC, tolerance 581
- specialized Dcsubsets, tolerance induction 1065–1066
- specialized lineage, cell differentiation 15
- specific culture conditions, tolerance induction 1027
- specific DC subsets, tolerance induction 1029–1031
- specific responses 185
- specific signature, *shistosoma mansoni* 186–189
- spleen
 - DC subtypes 204–206
 - FACS analysis 205
 - tolerogenic DC 523
- spontaneous maturation, DC 355
- sporozoites, malaria 651
- spread, HIV infection 774–776
- SR *see* scavenger receptors
- ST-HSCs *see* short-term HSCs
- STAg induced DC activation, *Toxoplasma gondii* 696
- staining of T cells, asthma 1067
- Staphylococcus aureus* 143, 156, 393
 - expression profile of pathogens 181
- Staphylococcus enterotoxin A* 359
- starting cell populations, CD34+ hematopoietic progenitor cells 27
- STAT *see* signal transducer and activator of transcription
- Stat3 18
- steady state
 - spleen cDC 210
 - tolerance induction 573
- steady state dendritic cell development, Flt3-license 18–20
- steady state expression levels, downregulation by sea 712
- steady state migration, DC 279–294, 530
- steady state versus infected mice, DC subtypes 202
- stem cells 27
 - hematopoietic 14
 - LC differentiation 39
- stimulation, strength 343–344
- stimulation of lymphocyte compartments, EBV 899
- stimulation signals, measles virus 863–864
- stomach, *h pylori* capture 135
- strains, HCMV 816
- strength, DC-Th-cell interaction 387
- strength of stimulation *see* stimulation
- Streptococcus pneumoniae* 146
- stress proteins, human cancer 1083
- stromal cells
 - DC differentiation 582
 - natural defense 405
- stromal lymphopoietin 7
- strong allogeneic mixed lymphocyte reaction 221
- strong Th1 polarization, EBNA1 901–902
- structural stability, systems biology 461
- structure, measles virus 856–857
- subpopulations
 - cytokines production 355
 - DC 176
- subsets, DC 466–468, 483–484
 - NK cells 485
 - tolerogenic DC 517–544
- subspecies, EBOV 830
- substandard virus-specific T cell responses, HIV infection 792–793
- subunit, soluble receptor-related 357
- sugar composition, apoptotic cells 600
- sulfated polysaccharides, HIV infection 793
- suppression, T cell tolerance 521
- suppressor cells, tolerance induction 578–579
- suppressor mechanisms, cancer vaccines 1104–1106
- suppressor T *see* Ts cells
- surface antigen heterogeneity, DC 201–202
- surface antigens, myelomonocyte surface antigens 36
- surface CD40 expression, *Toxoplasma gondii* 694
- surface expression, malaria 660
- surface interaction, measles virus 861
- surface molecules 569–590
 - tolerance induction 575–580
 - upregulation 731
- surface phenotype, pDCs/IPCs 224

- surface receptors, measles virus 860
- surface staining, markers 202
- survival time, renal cell carcinoma 1118
- susceptibility
 - HCMV 816
 - Leishmaniasis 670–673
- suspension cultures, plasmacytoid DC
 - development 36–38
- synapse, phagocytic 593
- synapses crossing, HIV infection 784
- synthetic ligands 321
- system biology, cell-t lymphocyte interaction
 - 455–480
- systemic administration, *Leishmania*
 - parasites 680
- systemic lupus erythematosus 237,
 - 239–240, 941
 - apoptotic cells 609
 - autoimmune diseases 938
 - DC numbers 947
 - defective abnormalities 947
 - pDC 947
 - plasma cell differentiation 948
 - type I IFN 948
- systems biology
 - DC activation 468–470
 - DC–CTL immunobiology 461–470
 - DC–CTL interactions 459
 - definition 457
 - feedback control 463
 - heterogeneous redundancy 460
 - immune system 460
 - MHC-restricted presentation 458
 - rapid perturbation 458
 - redundancy 460–461
 - structural stability 461
 - TCR-dependent signaling 459
- T**
- T-associated plasma cells 219
- T-bet, Th-cell responses 386
- T cell activation 313–384
 - chemokines 343
 - dendritic cells 343–354
 - effector cells 344
 - ICOS signaling 345
 - measles virus 864–865
 - pathways 345
 - receptor–ligand interactions 345
- T cell anergy, immature DC 525
- T cell clones, CHS 1049
- T cell-depleting agent, transplant tolerance
 - 1026
- T cell development
 - autoimmune diseases 949
 - CD83 888
- T cell differentiation
 - autoimmune diseases 944
 - cell fates 346
 - effector T cells 345–346
 - inhibitory cytokine TGF- β 346
- T cell expansion, measles virus 864–865
- T cell hyporesponsiveness, T cell tolerance
 - 1023
- T cell immunity 89
 - cancer vaccines 1097
 - dendritic cells 4
 - EBV specific 900
 - kinetic view 522
- T cell ligands, fungi 925–926
- T cell-mediated immune responses
 - 233–238
 - CMV 822
- T cell polarization, cancer vaccines 1100
- T cell-polarizing molecules 407
- T cell priming 347
- T cell progenitors 14
- T cell proliferation, CD83 887–888
- T cell-promoting DC 415–416
- T cell regulation 1000–1001
- T cell relocation, intestinal bacteria 763
- T cell responses 408–411
 - apoptotic cells 609
 - blood 1106
 - DC 349
 - EBNA1 901–902
 - EBV 903
 - factors 408–411
 - fungi 916
 - herpes simplex 85
 - HIV infection 792–793
 - pDC 349
 - plasticity 916
 - priming 348
 - *Schistosoma* 711
 - tuberculosis 746
- T cell specificity, tolerance induction 1003
- T cell stimulation 55
 - DC-based therapies 1037
 - HCMV 818
 - HSV-1 884–885
 - IL-6 360
- T cell subpopulations, tuberculosis 749
- T cell tolerance 1022–1026
 - allergies 520
 - anergy 519, 1023
 - Bet v 1 allergen 520
 - Ca²⁺ influx 519

- combinations
- cytokine-mediated suppression 521
- cytokines influence 1023
- DC-based therapy 1025
- deletion 519–520
- hyporesponsiveness 519
- ignorance 519
- immunoreactivity 520
- mechanisms 518–522
- migratory DC 530
- NF-AT activation 519
- regulation 521
- suppression 521
- T cell hyporesponsiveness 1023
- Treg cells 521, 1023–1025
- T cell viability, measles virus 864–865
- T cells 4, 405
 - antigen presentation 702–703
 - autoimmune diseases 937
 - CD8 + 427
 - DC-mediated HIV transmission 789
 - DC-NK cross-talk 489–490
 - graft-versus-host disease 973–974
 - IFN 386
 - immune regulation 1020
 - malaria 654
 - MMF 1000
 - nickel presentation 1047–1058
 - peripherally induced
 - pharmacological agents 1000
 - polarizing molecules 407
 - positive selection 208
 - proliferation 386
 - regulatory 489–490
 - thymus-derived naturally-occurring
 - tolerance 518–522
 - transplantation tolerance 987
 - tumor-specific 240
 - VD₃ 1000
- γδT cells 483
- T helper cells *see* Th cells
- T lymphocytes
 - cytotoxic 455–480
 - DC-CTL interaction 487–490
 - naïve 343–345
 - T-Nef, virus replication 783
- T regulatory cells, tolerance induction 569
- TAA *see* tumor-associated antigen
 - cancer vaccines 1103
- tagging enzyme, sage 625
- TAP *see* transporter associated proteins
 - *Salmonella* 727
- TAP blocking, HSV-1 884
- TAP dependence 440–441
- target tissues, monocyte entry 267–268
- targets
 - DEN 844
 - exosomes 500–501
- Tat, HIV infection 790
- TCR
 - cytotoxic T lymphocyte response 455
 - glycolipid recognition 315–316
 - nickel ions 1050–1051
 - semi-invariant 313
 - systems biology 459
- tegument proteins, HSV-1 878
- tenofovir, HIV infection 793
- Tf/TfR, tuberculosis 747
- TGF 32, 155
- TGF β1 39–41
 - signal mediation 64
- TGF β2, latent 103
- Th-cell development 388–392
- Th-cell polarization, Leishmaniasis 671
- Th cell responses 385–404
 - antigen doses 387
 - bone marrow-derived plasmacytoid DC 387
 - *Candida albicans* 390
 - CD11c⁺CD8α⁺ DC 388, 392
 - CD11c⁺CD8α⁺ DC 389, 392
 - concepts 388–392
 - co-stimulation 388
 - cytokines 386
 - filarial nematode glycoprotein ES-62 390
 - GATA-3 386
 - genetic background 388
 - IFN-γ 393
 - inflammatory molecules 391
 - ligand interaction 387
 - micro-environment 386
 - mouse dendritic cell populations 388
 - *Mycobacterium tuberculosis* 390
 - nematode glycoprotein ES-62 390
 - opposing concepts 388–392
 - pathogen recognition receptor 392
 - promotion 385–404
 - *Schistosoma* egg antigen 391
 - T-bet 386
 - thymic stromal lymphopoietin 391
 - Toll-like receptor 392
 - transcription factors 386
- Th cells
 - differentiation 130
 - Leishmaniasis 669, 671
 - polarization 682–683
- Th1 cells 385–426
 - development 386

- EBNA1 901–902
- fungi 926–927
- induction 235
- promoting DC 414–415
- semi-mature DC 529
- Th1 responses
 - cytokines production 359
 - DC-derived factors 408–411
 - priming 348
- Th1/Th2 balance, Leishmaniasis 672
- Th1/Th2 effector function bias, *Schistosoma* 709
- Th1/Th2 imbalance, autoimmune diseases 944
- Th2 cells 385–426
 - development 386
 - fungi 926–927
 - priming 348
 - promoting DC 415
- Th2 driven disorder, asthma 1059–1062
- Th2 induction 235
 - *Schistosoma* 714–717
- Th2 models, semi-mature DC 529
- Th2 responses
 - asthma 1068–1071
 - cytokines production 359
 - DC-derived factors 408–411
 - sea-specific 714
- Thamnomys rutilans*, malaria 653
- therapeutic control, HIV infection 796–797
- therapeutic T cell immunity, cancer vaccines 1097
- therapeutic vaccination
 - adenoviral gene transfer 1145–1153
 - biologically relevant peptides 1144
 - cancer 1143
 - gene transfer 1145–1153
 - gene transfer vectors 1145–1149
 - HLA-restriction pattern 1143
 - Leishmaniasis 687
 - manipulate DC biology 1145
 - manipulating ag presentation 1144
 - recombinant adenovirus 1146–1149
 - transfer of nucleic acids 1145
- therapeutical use
 - apoptotic cells 605–607
 - DC 1093–1172
- threshold
 - DC-CTL interaction 465
 - tolerance induction 570
- thrombopoietin 27
- Thrombospondin-1 *see* TSP-1
- thymic DC 208–209
 - tolerogenic DC subsets
 - transplantation tolerance 997
 - 204
- thymic stromal lymphopoietin 7
 - Th-cell responses 391
- thymocytes, apoptotic cells 603
- thymus-derived naturally-occurring, T cells
- TICAM-2 *see* TIR domain-containing adaptor
- tight junctions, intestinal epithelium 759
- TIL, renal cell carcinoma 1118
- time model, tolerance induction 1022
- TIR domain-containing adaptor 123
- tissue antigen presentation, cancer vaccines 1100
- tissue factor secretion, filoviruses 833
- tissue factors, modulation 395
- tissue homing receptors, imprinting 349
- tissue infiltration by DC, autoimmune diseases 945
- tissue location 319
- tissue macrophages, renewal 255
- tissue resident DC 175, 525
- tissues
 - *Leishmania*-infected 676
 - recruitment 267–269
- TLR 37, 105, 119–128
 - crosspresentation 435
 - cross-talk 156
 - DC 411–414
 - dendritic cell subsets 122
 - EBV 904
 - epithelial cells 762
 - Leishmaniasis 680
 - ligands 120
 - malaria 656
 - PTX3 168
 - *Schistosoma* 712
 - subfamilies 121–122, 231, 411–414, 436
 - Th-cell responses 392
 - tolerogenic DC 517
- TLR expression
 - differential 392
 - modulation 392–393
- TLR expression profiles, pDC 406
- TLR ligands, combined 394
- TLR ligation, myeloid DC 407
- TLR signaling 123
 - graft rejection 972
- TNF, autoimmune diseases 949
- TNF α 31–32, 39–42, 362
- TNF α production 143, 156
- TNF α cytokines 405
- TNF-R associated death domain 32
- TNF-R family blocking, asthma 1069

- TNF superfamily 31
- tolerance 569–590
 - autoimmune diseases 936–939
 - balance 608
 - dendritic cells 619–622
 - maintenance 405
 - self antigens 427
 - self-antigens 469–470
 - special DC 581–582
 - T cells 518–522
- tolerance associated
 - candidate genes 636–638
 - clinical relevance 638
 - esDC 637
 - functional impact 638
 - gene expression levels 636–637
 - genes 619–648
 - simultaneous assessment 636–637
 - transcript expression pattern 636
- tolerance associated genes 619–648
 - candidates 630, 636–638
 - ECM 633
 - expression 629–632
 - identification 628, 630
 - modulated DC populations 629–632
 - signatures 632–634
- tolerance candidates, functional relevance 637
- tolerance induction 569–590, 1002–1004, 1027, 1065–1066
 - activated DC 574
 - activation-induced cell death 570
 - AIRE 569
 - antigens 110, 569, 572–573, 1022
 - apoptotic cells 1004
 - bone-marrow derived DC 570
 - carbohydrate recognition domains 571
 - cell death 570
 - clonal anergy 569
 - clonal deletion 569
 - CLR 571
 - complement receptors 578
 - C-type lectin receptors 571–573
 - DC 569–590, 1006–1007, 1021, 1029–1031
 - DC-based therapies 1035–1038
 - dead cells uptake 578
 - DEC-205 572–573, 575
 - dose 1022
 - embryoid bodies 1006
 - endocytic receptors 569
 - epithelial cells 570
 - ESDC 1006
 - Fc receptors 578–579
 - genetic engineering 1028–1029
 - ILT 580–581
 - immune regulation 1021
 - immunosuppressive drug 1032
 - indirect pathway 1002–1004
 - inhibitory molecules 580–581
 - integrin 577–578
 - lectin receptors 571–573
 - lethal autoimmunity 576
 - lung 1065–1066
 - medullary epithelial cells 570
 - negative signal induction 577–579
 - notch ligands 579–580
 - peripheral 573, 575–577
 - pharmacological manipulation 1027–1028
 - receptors 572–573, 577–579
 - recipient DC 1032
 - regulatory T cells 578–579
 - resting DC 574–575
 - resting DC preservation 577–579
 - self-reactive T cells 1021
 - semi-direct pathway of presentation 1002
 - signal induction 577–579
 - specialized Dcsubsets 1065–1066
 - specific culture conditions 1027
 - specific DC subsets 1029–1031
 - steady state 573
 - suppressor cells 578–579
 - surface molecules 575–580
 - T cell tolerance 1022–1026
 - T cells specificity 1003
 - T regulatory cells 569
 - threshold 570
 - time model 1022
 - tolerance induction 580–581
 - transcription factor 569
 - transmembrane receptors 577
 - tunable activation threshold model 1022
- tolerance model 638
- tolerogenic capacity, transplantation tolerance 994–996
- tolerogenic DC 517–648
 - administration 1003
 - apoptotic cells 523
 - autoimmune diseases 944
 - DC subsets *in vivo* 522–524
 - DC-based therapies 1037–1038
 - dendritic cells 517–648
 - differentiation stages 517–544
 - environmental signals 523
 - generation 518
 - lymph nodes 523
 - maturation resistance 528

- pathogen recognition receptors 517
- pDC 524
- *Schistosoma* 714
- spleen 523
- subsets 517–544
- TLR 517
- transplant tolerance 1035
- transplantation tolerance 994, 1001–1002
- tolerogenicity, importance of maturation resistance 528
- Toll Like Receptors *see* TLR
- tonsillar NK cell activation, EBV 899
- toxic shock syndrome toxin-1 387
- Toxocara canis* 712
- Toxoplasma gondii* 414
 - antigen presentation 702–703
 - DC activation 694–698
 - DC function *in vivo* 703–704
 - DC regulatory functions 693–708
 - DC sentinel function 693–708
 - DC subpopulations 694–696
 - host receptors 696–698
 - IFN- γ synthesis 693
 - immune polarization 700
 - immune response 693–708
 - immunodeficiency 693
 - lipoxin 699
 - 5-lipoxygenase-dependent pathway 700
 - murine DC 696–698
 - parasite ligands 696–698
 - parasitophorous vacuoles 702
 - pathways 698
 - protease sensitive 697
 - protozoan 693
 - signaling pathway 696
 - STAg induced DC activation 696
 - surface CD40 expression 694
 - Th2-cell development 395
 - virulence 704
 - human DC activation 698
- TPCK 55
- TPO *see* thrombopoietin
- TRADD *see* TNF-R associated death domain
- TRAM *see* TIR domain-containing adaptor
- trans-receptor, HIV-1 133
- transcript expression pattern, tolerance associated 636
- transcript profiling 623
- transcription effects, innate immunity 181
- transcription factor knockout mice, DC phenotypes 58–59
- transcription factors 4, 261
 - deciphering 53–71
 - helix-loop-helix 63
 - Langerhans cells 77
 - Pax5 60
 - Th-cell responses 386
 - tolerance induction 569
- transcription units 856
- transcriptional profile, DC 185
- transcriptional response, pro-inflammatory 190
- transcriptomics 178
- transduced cells, adenovirus 1146
- transductional targeting, adenovirus 1148
- transfection efficiencies 1155
- transfection of nucleic acids 1154–1160
- transfer, membrane proteins 504–506
- transfer of nucleic acids, therapeutic vaccination 1145
- transferrin, tuberculosis 747
- transforming growth factor *see* TGF
- transgenes, ES cells 1006
- transient T cellular immunosuppression, HCMV 813
- translocation, antigen 464
- transmembrane glycoproteins, trimeric type ii 143
- transmembrane proteins
 - Flt3 ligand 28
 - type II 408
- transmembrane receptors, tolerance induction 577
- transmissible spongiform encephalopathies, pathogenesis 287–288
- transmission, viruses 134
- transmission EM, pDCs-IPCs 223
- transplant vascular sclerosis, DC therapy 1033
- transplantation 7, 967–1046
- transplantation tolerance 983–1046
 - adaptive Treg 992
 - alloantigen presentation 985–987
 - allograft rejection 985–989
 - allograft survival 1026
 - antigen delivery 995
 - antigen-specific tolerance 985
 - B cells increase 1034
 - cellular markers 1034–1035
 - CRT 984
 - DC 985–989, 993–1002
 - DC subsets 990
 - direct alloantigen presentation 985–986
 - donor bone marrow 999
 - donor hematopoietic cell microchimerism 1026
 - DTH reactions 990

- endogenous male antigen presentation 998
- enhanced tolerogenic capacity 994–996
- ES cells 984, 988
- FasL expression 1001
- genetic modification 1001–1002
- hematopoietic stem cells 999
- hyperacute rejection 983
- IDO 992–993
- IFN-producing cells 991
- IL-10 gene 1001
- immune responsiveness suppression 996
- indirect alloantigen presentation 986–987
- killer DC 1001
- life expectancy 983
- maturation status of DC 994–997
- MHC gene matching 984
- mixed chimerism 999
- NK cell reduction 1034
- passenger leukocyte 985
- pathway 987
- pDC 991
- peri-transplant treatment 1026
- pharmacologically-treated DC 1001
- self-tolerance 989–997
- semi-direct alloantigen presentation pathway 987
- semi-mature cells 997
- sensitization 986
- T cell-depleting agent 1026
- T cells 987
- thymic DC 997
- tolerogenic capacity 994–996
- tolerogenic DC phenotype 1035
- tolerogenic phenotype reinforcement 1001–1002
- viable organs 983
- viral gene homolog 1001
- zoonosis 983
- transport, major antigen 678–680
- transporter associated proteins 437
- travel medicine, Leishmaniasis 669
- Treg cells *see* regulatory T cells
- Trichuris muris* 712
- trigger point for immunity 996–997
- triggering of autoimmunity 940
- troglodytosis
 - protein swapping 508
 - protein transfer 506
- tropism, filoviruses 832
- tropism-modification, adenovirus 1150
- troxolone necrosis, protein transfer 506
- Trypanosoma*, exogenous ligands 320
- Trypanosoma cruzi*, apoptotic cells 607
- tryptophan catabolism 1086
- tryptophan metabolic pathway, fungi 924–925
- Ts cells, tolerance induction 580
- TSE *see* transmissible spongiform encephalopathies
- TSLP, thymic stromal lymphopoietin
- TSP-1
 - antiangiogenic activity 147
 - apoptotic cells 596
- TSST-1 *see* toxic shock syndrome toxin-1
- tuberculosis 745–758
 - acid-fastness 748
 - antigen presentation 749–752, 755
 - apoptotic blebs 754
 - BCG 745, 749
 - co-infection with HIV 747
 - crosspriming 753–754
 - C-type lectins 747
 - DC function diversion 755
 - DC-SIGN 747
 - detour pathway
 - endosomal phagosomes 753
 - facultative intracellular parasites 747
 - Ghon complex 746
 - granuloma 746
 - immune modulating APC 750
 - immune response 749
 - immune system activation 746
 - intracellular pathogens 747–748
 - latency 746
 - lipoproteins 755
 - LTP 750
 - lung-derived DC 749
 - MHC-I pathway 754
 - mycobacteria 747–748, 752, 755
 - MyD88 754
 - PAMP 750
 - pro-inflammatory cytokines 753
 - regulatory cells 752–753
 - saposin 750
 - skin-test-positive donors 750
 - T cell response 746
 - T cell subpopulations 749
 - Tf/TfR 747
 - transferrin 747
 - vaccine strain 745
- tumor antigens 1082, 1085, 1129–1142
 - cross-presentation 488
 - DC vaccination 1133
- tumor associated antigens 137
 - renal cell carcinoma 1121

- tumor-cell-derived exosomes 503
tumor cells
– DC vaccination 1131–1132
– recognition 427
tumor-derived exosomes 499
tumor growth, activated NKT cells 325
tumor immunity, human cancer 1081
tumor-infiltrating lymphocytes *see* TIL
tumor infiltration, immature myeloid DCs 240
tumors interference, normal DC function 1084–1087
Tumor Necrosis Factor *see* TNF
tumor rejection 488
tunable activation threshold model, tolerance induction 1022
tuning, DC activation 468–470
tuning dendritic cell migration 303–305
turnover time 15
two-color microarrays 178
two-step culture system, renal cell carcinoma 1119–1120
type 1 reovirus, intestinal epithelium 766
type 3 complement receptor 408
type I allergy 1047
type I IFN 221, 237–238, 349, 356–357, 406
– autoimmune diseases 949
– family 409
– HSV-1 881
– myeloid DCs 233
– pDCs-IPCs 229–230
– producing cells 219–252
– receptors 61, 230–231
– SLE 948
– *see also* interferon
type II IFN, receptor 61
type II transmembrane proteins, C-type lectins 408
type III secretion system 729
tyrosine kinase Flk-2 258
- U**
uptake, apoptotic cells 155, 601
– exosomes 501–502
– heat shock protein-peptide complexes 1132
– *Salmonella in vivo* 734–737
- V**
vaccinating ability, fungi 925
vaccination
– against fungi 915
– cancer 1095–1116
– Leishmaniasis 685–686
vaccine strain, tuberculosis 745
vaccines
– dendritic cells 8–9
– design 7–9
– HIV infection 793
Vaccinia virus 795
– pathogen recognition 125
Vaccinia virus-based vectors, adenovirus 1149
vacuolar pathway 440–441
Var genes, malaria 652
variant surface antigens (VSA), malaria 656
VD₃, T cells regulation 1000
vectors
– exosomes 503
– microbial 8
VEGF, human cancer 1085
vero cell line, filovirus replication 833
vesicle secretion, exosomes 502
vesicles, endocytic 434
vhs (virion host shutoff) gene 876
viable organs, transplantation tolerance 983
Vibrio cholerae 416
vicious circle, autoimmune diseases 945
viral factors, modification of moDC 790
viral gene homolog, transplantation tolerance 1001
viral IL-10, HCMV 820
viral immediate-early proteins, HSV-1 875
viral infections
– DC-NK cross-talk 490–491
– pDCIPC induction 237
viral stimulation 229
viral vectors 637
– HIV infection 794
virion host shutoff (vhs) 876
virulence, *Toxoplasma gondii* 704
virus amplification, HIV infection 776
virus-carrying immature DCs, HIV 792–793
virus-DC-SIGN interactions, prototypic example 133–134
virus fate, DC maturation state 787
virus internalization, adenovirus 1146
virus-like particles *see* VLP
virus movement, HIV infection 784
virus replication
– DC-T cell milieu 783–784
– HCMV 819
– inhibition 356
virus-specific T cell responses, HIV infection 792–793
virus spread, phases 786

virus structure, measles virus 856
viruses 773–914
– cellular resistance 61
visceral Leishmaniasis 673
VLP, filoviruses 834
Vpr, HIV infection 790
VSA (variant surface antigens), malaria 656

W

wild type MV viruses, lymphotropic 857
wild type *Salmonella* 727
wild type strains, measles virus 857
Wiskott-Aldrich syndrome, defective abnormalities in DC 947
Wnt 54

X

xeno-antigen, renal cell carcinoma 1121

Y

yolk sac 257
YS *see* yolk sac

Z

Z protein, LCMV 839
ZEBOV GP harboring pseudotypes entry, DC-SIGN 842–843
zinc finger DNA binding proteins 54
zoonosis, transplantation tolerance 983
zymosa, bound by PTX3 167
zymosan 411–412